There is a medical staging system that classifies exactly where a woman is in the menopausal transition. It was developed by international experts from five countries, endorsed by the North American Menopause Society, the American Society for Reproductive Medicine, the International Menopause Society, and the Endocrine Society, and published simultaneou…

Read more

Maria is 43. She has always been the sharpest person in any meeting. Last month she forgot the name of a colleague she has worked with for six years. She stood in the cereal aisle of her grocery store, unable to remember what she came for. Her period, which arrived like clockwork for 30 years, showed up nine days early, then skipped a month entirely.

Free Tools for Everyone:

• Understanding Bladder Leakage

• Menopause Treatment Options

More Tools HERE

Her doctor told her she was “too young for menopause” and suggested she might be stressed.

Maria is not stressed. Maria is in perimenopause. And she deserved a doctor who recognized it.

Perimenopause is the transition your body makes on its way to menopause. It typically begins in the mid-40s, but a 2025 study of more than 4,400 U.S. women published in npj Women’s Health found something striking: over 55% of women aged 30 to 35 already reported moderate to severe perimenopause-related symptoms [1]. That number climbed to 64% for women aged 36 to 40.

Yet most women do not seek treatment until age 56 or older.

That gap should concern every ObGyn in America.

The problem is not that women ignore their symptoms. The problem is that nobody tells them what to look for. Anticipatory guidance about puberty is embedded in our schools. Pregnancy gets an entire prenatal care infrastructure. Perimenopause? Women are left to figure it out alone, often told their symptoms are “just stress” or “just aging.”

A 2024 study in the journal Menopause described the experience perfectly. Researchers found that 63% of perimenopausal women reported “not feeling like myself” at least half the time [2]. That phrase captures something important: these symptoms are real, they are measurable, and they have specific hormonal explanations.

Here are seven warning signs your body may be approaching menopause, and the numbers behind each one.

Read more

Something remarkable happened in 2025. After being ignored, dismissed, and undertreated for generations, menopause became a legislative priority. Not in one state—in nineteen. Not with one bill—with thirty-six.

And then, in November, the FDA did something many of us thought we’d never see: they removed the “black box” warning from hormone therapy products. The same warning that scared millions of women away from effective treatment for over two decades.

This is what progress looks like. And 2026 is shaping up to be even bigger.

The Legislative Breakthrough

Let’s take stock of where we are. In the past year alone:

Four states now mandate insurance coverage for menopause treatments. Illinois and Louisiana require coverage for all patients. Oregon and Washington cover some patients. New Jersey joins them with the Menopause Insurance Coverage Act, signed into law by Governor Phil Murphy.

California passed a bill requiring insurance coverage and improving menopause education for healthcare providers—and Governor Gavin Newsom vetoed it. Twice. Despite bipartisan support. He’s indicated he may include provisions in the state budget, but that’s temporary. California advocates will need to keep pushing for permanent law.

Rhode Island now provides workplace protections for employees on the basis of menopause. Philadelphia passed a similar ordinance taking effect in 2027.

Maine requires its Department of Health and Human Services to provide menopause informational materials.

Illinois created a permanent statewide Menopause Awareness Week.

This is unprecedented. Menopause—a biological reality affecting half the population—is finally being treated as a legitimate healthcare issue worthy of legislative attention.

Subscribe now

The Black Box Is Gone

On November 10, 2025, the FDA announced it would remove the black box warning from all hormone therapy products containing estrogen. This is the strongest warning the agency can place on a medication, and it had been there since 2003.

For twenty-three years, that label told women and their doctors that hormone therapy increased the risk of breast cancer, heart disease, stroke, and dementia. Prescriptions plummeted. Use dropped from 27% of menopausal women in 1999 to just 5% by 2020.

Millions of women suffered through hot flashes, night sweats, sleep disruption, mood changes, vaginal atrophy, and accelerated bone loss—because they were afraid to take a medication that could have helped them.

“This is, in my opinion, one of the greatest mistakes in modern medicine—the demonization of hormone replacement therapy,” said FDA Commissioner Marty Makary at the announcement.

He’s not wrong.

How We Got Here: A Story of Bad Science and Worse Communication

The black box warning came from the Women’s Health Initiative (WHI), a large study that reported alarming findings in 2002. Headlines screamed about breast cancer risk. Doctors stopped prescribing. Women flushed their pills.

But here’s what got lost: the WHI enrolled women with an average age of 63—well past menopause. Many already had cardiovascular disease. The study wasn’t designed to answer the question most relevant to symptomatic menopausal women: Is hormone therapy safe for women in their 40s and 50s who are having symptoms?

Subsequent analysis told a different story. Women who start hormone therapy within 10 years of menopause onset, or before age 60, show:

• Reduced all-cause mortality

• 50% reduction in heart attack risk

• 35% lower risk of Alzheimer’s disease

• 50-60% reduction in bone fractures

The WHI scared women away from treatment that, for most, would have helped them. The FDA’s original warning painted all women with the same brush, ignoring the critical importance of timing.

The new guidance recommends starting systemic hormone therapy within 10 years of menopause onset or before age 60. This is evidence-based medicine—finally.

What the FDA Change Means (and Doesn’t Mean)

Let me be clear about what’s changed:

The black box warning is being removed from all estrogen-containing products. This includes pills, patches, gels, creams, and vaginal estrogen.

The warning about endometrial cancer for estrogen-only products remains. Women with a uterus who take systemic estrogen still need progesterone to protect the uterine lining. That hasn’t changed.

Individual risk assessment still matters. Women with a history of breast cancer, blood clots, or certain other conditions need careful, individualized discussions with their providers. Removing the black box doesn’t mean hormone therapy is right for everyone.

Vaginal estrogen is extremely safe. The removal of the warning from low-dose vaginal estrogen is particularly welcome. This treatment—used for vaginal dryness, painful sex, and recurrent urinary tract infections—has an excellent safety profile and was being avoided unnecessarily because of the scary label.

The American College of Obstetricians and Gynecologists applauded the change, while noting that systemic hormone therapy still requires nuanced discussion. As ACOG President Dr. Steven Fleischman put it: “The updated labels will better allow patients and clinicians to engage in a shared decision-making process, without an unnecessary barrier.”

That’s exactly right. The goal isn’t to put every woman on hormones. The goal is to remove fear-based obstacles to an informed conversation.

What’s Coming in 2026

If 2025 was the year menopause got attention, 2026 is the year to cement the gains.

States to watch:

• Michigan has four live bipartisan bills supporting initiatives like statewide medical school curriculum and public education campaigns. Governor Gretchen Whitmer made menopause the topic of a listening tour.

• New Jersey has additional proposals on the table beyond the insurance coverage law: bills for physician licensing credits, an inter-agency council on menopause research, and state-supported treatment services.

• New York, Florida, Georgia, and Virginia all have momentum building.

Federal action:

Several bills were introduced over the past two years:

• The Improving Menopause Care for Veterans Act

• The Advancing Menopause Care and Mid-Life Women’s Health Act

• The Menopause Research and Equity Act

• The WARM (We’re Addressing the Realities of Menopause) Act

Getting these through Congress will be difficult given the current political environment. But the FDA’s action on the black box warning creates an opening. When the regulatory agency acknowledges that hormone therapy has been unfairly maligned, Congress has political cover to invest in menopause research and education.

What the FDA still needs to do:

Testosterone. Women increasingly use testosterone as part of menopause care—for libido, energy, and muscle maintenance—but the FDA only approves it for men. An FDA-approved women’s formulation, backed by research and appropriate dosing guidelines, is an important next step.

What This Means for Patients

If you’re a woman in perimenopause or menopause, here’s what you should know:

The conversation has changed. Your doctor should no longer reflexively refuse hormone therapy based on outdated fears. If they do, find a provider who stays current with the evidence.

Timing matters. The benefits of hormone therapy are clearest when started within 10 years of menopause onset or before age 60. This is the “window of opportunity” that the WHI obscured.

Vaginal symptoms deserve treatment. Vaginal estrogen is safe for the vast majority of women, including many breast cancer survivors. Don’t suffer from painful sex or recurrent UTIs because of a warning label that’s being removed.

Insurance coverage is expanding. Check whether your state mandates coverage. If not, advocate for it. The legislative language now exists—it just needs to be adopted.

Your symptoms are real. Hot flashes, night sweats, insomnia, brain fog, mood changes, weight gain—these aren’t minor inconveniences. For many women, they’re debilitating. You deserve treatment.

The Bigger Picture

Menopause affects roughly half the human population. The average woman spends a third of her life post-menopause. And yet, until recently, medical schools taught almost nothing about it. Insurance often didn’t cover treatment. Research funding was negligible.

The past year represents a turning point. Legislative action, regulatory reform, and private investment—like the Gates Foundation’s $2.5 billion commitment to women’s health, including $100 million specifically for menopause research—are finally treating this as the public health priority it is.

But there’s still work to do. As menopause advocate Jennifer Weiss-Wolf notes, the movement must prioritize women at the margins: those facing domestic violence, addiction, incarceration, poverty. If standard menopause care is inadequate for resourced women on a good day, it’s exponentially worse for those already underserved by the healthcare system.

What You Can Do

Know your options. If you’re symptomatic, talk to your provider about hormone therapy. Understand the timing considerations. Ask about vaginal estrogen if you have genitourinary symptoms.

Advocate. Contact your state legislators. The legislative language exists. California’s bill can be adapted for any state. Rhode Island’s workplace protections can be replicated. Your voice matters.

Demand coverage. If your insurance doesn’t cover menopause treatments, push back. File appeals. Write to your employer’s benefits team. The more patients demand coverage, the faster it becomes standard.

Stay informed. The science is evolving. The Menopause Society, ACOG, and reputable medical sources provide evidence-based information. Be wary of social media claims—both the fear-mongering and the oversimplification.

A Turning Point

For decades, menopause was treated as something women should just endure. Hot flashes? Deal with it. Vaginal atrophy? That’s just aging. Sleep disruption? Try relaxation techniques.

That era is ending. The black box warning is coming off. States are mandating coverage. Research funding is increasing. Medical education is improving.

It took too long. Millions of women suffered unnecessarily. But we’re finally moving in the right direction.

2025 was the breakthrough year. 2026 is the year to make it permanent.

She is 44. She is in her gynecologist’s office because she cannot stop yelling at her children. Not the normal frustration of parenting. Rage. The kind that comes from nowhere, floods her body, and leaves her shaking. She cried in the car afterward. She thought something was wrong with her marriage. Her therapist suggested perimenopause. Her gynecologist ran a thyroid panel and told her everything was normal.

She went home without an answer.

She also did not mention the other things. The words she cannot find in meetings. The knee pain she blamed on running. The nights she lies awake from 2 a.m. to 4 a.m. staring at the ceiling. The period last month that soaked through a super tampon in 45 minutes.

She did not mention them because she did not know they were connected.

Here is the problem: perimenopause has more than 30 documented symptoms. Most women know about hot flashes. Most doctors were trained to look for hot flashes. But the menopausal transition typically begins 4 to 7 years before the final menstrual period, and the earliest symptoms are often the ones nobody talks about.

The Training Gap

Only 31% of OB-GYN residency programs in the United States have a dedicated menopause curriculum. Ninety-three percent of program directors agree residents need one. Eighty percent of graduating internal medicine residents do not feel competent to discuss or treat menopause [1,2].

That means the doctor you trust with your reproductive health may have received fewer than two lectures on menopause during four years of specialty training.

It is not your doctor’s fault. It is a training failure. But you are the one living with the consequences.

The Numbers

The Study of Women’s Health Across the Nation (SWAN), the largest and longest study of the menopausal transition, followed over 3,300 women for more than two decades. Here is what they found:

• Perimenopause can begin as early as the late 30s, though most women enter it between 45 and 55

• Up to 70% of perimenopausal women report significant irritability

• More than 50% experience sleep disturbance

• Joint pain affects roughly 50% of women during the menopausal transition

• Brain fog (cognitive difficulty) is a documented, measurable phenomenon during perimenopause, though it appears to be temporary

• Up to 78% of women aged 40 to 54 report heavy menstrual bleeding

• Women in late perimenopause are 71% more likely to experience depression than when they were premenopausal [3,4,5]

These are not rare complaints. These are the majority experience. Yet many women cycle through multiple doctors before someone connects the dots.

Why Your Doctor Misses It

Perimenopause is a clinical diagnosis. According to the STRAW+10 staging system, the international gold standard, the hallmark of early perimenopause is a persistent change in menstrual cycle length of 7 or more days. No blood test is required [6].

But here is the catch: many of the most disruptive symptoms appear while periods are still regular. The SWAN data showed that cognitive difficulties, mood changes, and sleep disruption can begin years before menstrual irregularity. If your doctor is waiting for skipped periods or an elevated FSH to confirm perimenopause, you may suffer for years without explanation or treatment.

The following 9 questions are designed to help you recognize perimenopause symptoms your doctor might overlook, and to give you specific language for your next appointment.

1. “I’ve been having episodes of intense anger that feel out of proportion. Could this be perimenopause?”

Up to 70% of perimenopausal women report significant irritability, and for many it is their most bothersome symptom. Fluctuating estrogen and progesterone directly affect serotonin, the neurotransmitter that regulates mood. This is not a character flaw. It is neurochemistry.

What to do now:

• Tell your doctor the rage is new and feels different from normal stress or frustration

• Track episodes for one to two months alongside your menstrual cycle to show a pattern

• Ask specifically: “Could hormone fluctuations be causing this?” If your doctor dismisses the question, consider seeing a menopause-certified practitioner (The Menopause Society maintains a provider directory at menopause.org)

• Treatment options with evidence include hormone therapy, SSRIs (which can be used at lower doses than for depression), and cognitive behavioral therapy

2. “I’m having trouble finding words and concentrating. Is this normal for perimenopause?”

The SWAN study documented a measurable decline in processing speed and verbal memory during perimenopause. The good news: this appears to be temporary, resolving in postmenopause. The critical distinction is that test scores did not drop in absolute terms. They simply stopped improving with repeated testing, which is the normal pattern for this age group [7].

What to do now:

• Describe specific cognitive changes: word-finding difficulty, losing your train of thought, trouble concentrating at work

• Ask your doctor to rule out thyroid disease, sleep apnea, depression, and vitamin B12 deficiency, all of which can mimic perimenopause brain fog

• Do not accept “you’re just getting older” as an explanation. Perimenopausal cognitive changes are driven by the menopausal transition, not aging alone

• Prioritize sleep. SWAN data showed that sleep disruption and mood symptoms had independent negative effects on cognitive performance

3. “My joints hurt, especially in the morning. Could declining estrogen be causing this?”

Approximately 50% of perimenopausal women experience joint pain. Estrogen is a potent anti-inflammatory, and its decline allows inflammation to increase in weight-bearing and small joints. Many women are sent to rheumatologists or given arthritis diagnoses before anyone considers hormonal contribution [5].

What to do now:

• Ask your doctor: “Could my joint pain be related to perimenopause?” If the answer is “I don’t know,” that is an honest answer, and you should ask for a referral to someone who does

• Request basic inflammatory markers (ESR, CRP) and rheumatoid factor to rule out autoimmune disease

• Hormone therapy has been shown to reduce musculoskeletal pain in menopausal women. This is a conversation worth having

• Low-impact exercise (swimming, yoga, walking) and omega-3 fatty acids may help

4. “I wake up at 2 or 3 a.m. and cannot fall back asleep. Is this a perimenopause pattern?”

More than half of perimenopausal women report sleep disturbance. SWAN found that sleep complaints increase significantly during the menopausal transition, independent of aging. The pattern is characteristic: falling asleep is often fine, but staying asleep is not. Waking in the early morning hours and being unable to return to sleep is a hallmark [3].

What to do now:

• Describe the specific pattern to your doctor. “I wake at 2 a.m. and lie awake for hours” is different from “I have trouble falling asleep” and points to different causes

• Ask about night sweats even if you do not notice them. Some women wake from vasomotor episodes without recognizing the heat

• Ask whether low-dose hormone therapy or specific sleep interventions (not just “sleep hygiene”) are appropriate

• If your doctor prescribes a sleep aid without asking about your menstrual cycle, that is a red flag. The cause matters

5. “My periods are suddenly much heavier, with flooding and large clots. Should I be concerned?”

Up to 78% of women aged 40 to 54 report heavy menstrual bleeding. During perimenopause, anovulatory cycles become more common. Without ovulation, progesterone is not produced, estrogen builds the uterine lining unchecked, and when it finally sheds, the bleeding can be sudden and severe. This is called “flooding,” and it is not your imagination [8].

What to do now:

• Quantify your bleeding: How many pads or tampons per hour? How many days? Normal blood loss is 30 to 45 ml per cycle (6 to 9 soaked regular pads total). More than 80 ml (16 soaked pads) meets the definition of menorrhagia

• Ask your doctor to check your hemoglobin and ferritin. Heavy bleeding causes iron deficiency, and iron deficiency causes fatigue, brain fog, and mood changes that compound your other symptoms

• Ask about a transvaginal ultrasound to rule out fibroids or polyps, which become more common in the 40s

• Treatment options include tranexamic acid (taken only during bleeding), the levonorgestrel IUD (highly effective), hormonal contraceptives, and cyclic progesterone

6. “I feel anxious for no reason. I have never been an anxious person. What changed?”

SWAN documented that women in perimenopause are significantly more likely to experience anxiety and depressive symptoms than when they were premenopausal. Late perimenopause carries the highest risk. For some women, this is their first experience of mood disturbance. Fluctuating estrogen affects serotonin, norepinephrine, and GABA, all of which regulate anxiety [4,9].

What to do now:

• Tell your doctor this is new. The words “I have never felt like this before” carry clinical weight

• Ask specifically whether hormone therapy might address the underlying cause rather than starting with an SSRI alone (though SSRIs can be appropriate and effective)

• If you are prescribed an antidepressant, ask: “Are we treating perimenopause or depression?” The answer should be thoughtful, not reflexive

• CBT has evidence for perimenopausal mood symptoms, including an internet-based format

7. “My heart races randomly, sometimes when I am sitting still. Could this be hormonal?”

Heart palpitations during perimenopause are common but underrecognized. Estrogen fluctuations can affect the electrical conduction system of the heart and cause episodes of rapid or irregular heartbeat. These are usually benign but terrifying, and many women end up in emergency departments or with cardiology referrals before anyone mentions hormones [5].

What to do now:

• Get a basic cardiac workup first. An EKG and thyroid panel are reasonable to rule out arrhythmia and hyperthyroidism

• Once cardiac causes are excluded, ask: “Could these palpitations be related to perimenopause?”

• Track when they happen. If they cluster around your period or in the second half of your cycle, that supports a hormonal cause

• Reduce caffeine and alcohol, both of which can worsen hormonally mediated palpitations

8. “I have zero interest in sex. My partner thinks it is about our relationship. Is it physical?”

Declining estrogen and testosterone both contribute to decreased libido during perimenopause. Vaginal dryness (which begins earlier than most women expect) makes sex uncomfortable, and discomfort makes desire disappear. SWAN found that sexual functioning declines most dramatically in the 20 months surrounding the final menstrual period [3].

What to do now:

• Name the problem directly: “My libido has decreased and I want to understand why”

• Ask about vaginal estrogen, which is local (not systemic), has minimal absorption, and is effective for dryness and pain with intercourse

• Ask whether systemic hormone therapy or other options might address the broader picture

• Do not let your doctor dismiss this as “normal aging.” Treatable causes deserve treatment

9. “I have gained weight around my middle despite no changes in diet or exercise. Is this metabolic?”

Body composition changes during the menopausal transition are driven by shifting estrogen, which influences where fat is stored. The redistribution of fat to the abdomen is not cosmetic. It is metabolic. Visceral fat increases cardiovascular risk, and the menopausal transition accelerates unfavorable changes in lipids and vascular health [3].

What to do now:

• Ask for a fasting lipid panel and fasting glucose or HbA1c. The menopausal transition is when cardiovascular risk begins to climb

• Ask your doctor about the cardiovascular implications of the menopausal transition, not just the symptoms

• Resistance training becomes critical during this period. It protects bone density, preserves muscle mass, and improves metabolic health

• Hormone therapy, when initiated early, may help attenuate these metabolic changes

The Bigger Picture

If you recognized yourself in three or more of these questions, you are probably in perimenopause. You do not need a blood test to confirm it. You need a doctor who will listen to your symptoms, connect them to the menopausal transition, and discuss your treatment options.

Eighty-five percent of perimenopausal and menopausal women experience symptoms that affect their quality of life. Sixty percent seek medical help. Seventy-five percent go untreated [10].

That is not a patient problem. That is a professional failure.

You deserve a doctor who knows what perimenopause looks like when it does not start with a hot flash. If your current provider cannot give you that, find one who can. The Menopause Society (menopause.org) maintains a directory of certified practitioners. Use it.

Your body is not broken. Your hormones are changing. And there is a name for what you are feeling, even if your doctor has not said it yet.

Hot Tip: Copy this and bring it to your next appointment.

“I am [age]. Over the past [months], I have noticed [list your symptoms: rage/irritability, brain fog, joint pain, insomnia, heavier periods, anxiety, palpitations, low libido, weight changes]. I have read that these can be symptoms of perimenopause and that perimenopause is a clinical diagnosis that does not require blood work to confirm. I would like to discuss whether the menopausal transition could explain what I am experiencing, and what my treatment options are.”

You do not need to justify this request. You do not need to apologize for it. You are asking your doctor to do their job.

If this post helped you understand what is happening in your body, share it with a friend in her 40s who is wondering the same thing. Evidence should reach the people it is meant to protect.

Subscribe to ObGyn Intelligence for more evidence-based analysis of the practices that shape your care.

Subscribe now

References

1. Allen JT, et al. Needs assessment of menopause education in United States obstetrics and gynecology residency training programs. Menopause. 2023;30(10):999-1003.

2. Christianson MS, et al. Menopause education: needs assessment of American obstetrics and gynecology residents. Menopause. 2013;20(11):1120-5.

3. El Khoudary SR, Greendale G, Crawford SL, et al. The menopause transition and women’s health at midlife: a progress report from the Study of Women’s Health Across the Nation (SWAN). Menopause. 2019;26(10):1213-27.

4. Bromberger JT, Kravitz HM, Chang YF, et al. Major depression during and after the menopausal transition: Study of Women’s Health Across the Nation (SWAN). Psychol Med. 2011;41(9):1879-88.

5. Menopause Symptoms. Let’s Talk Menopause. Available from: https://www.letstalkmenopause.org/symptoms. Accessed February 2026.

6. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012;19(4):387-95.

7. Greendale GA, Derby CA, Maki PM. Perimenopause and cognition. Obstet Gynecol Clin North Am. 2011;38(3):519-35.

8. Dreisler E, Frandsen CS, Ulrich L. Perimenopausal abnormal uterine bleeding. Maturitas. 2024;184:107944.

9. Avis NE, Crawford S, Bromberger JT, et al. Depressive symptoms over the final menstrual period: Study of Women’s Health Across the Nation (SWAN). J Affect Disord. 2025;369:218-26.

10. Addressing the Knowledge Gap: Menopause. CRMC. Available from: https://www.cuyunamed.org/knowledge-hub/addressing-the-knowledge-gap-menopause/. Accessed February 2026.

She’s 52. Active. Runs three miles twice a week. Eats well. Takes a multivitamin. She mentioned to her gynecologist that her mother broke a hip at 72. She asked if she should get a bone density scan.

Her doctor said no. Not yet. Guidelines say 65.

So she went home. Reassured. She’ll think about it again in 17 years.

By then, she may have lost up to 20% of her bone mineral density. The first fracture will be her screening test.

This is how we manage bone health in women. We wait until the damage is done, call it prevention, and act surprised when bones break.

The Biology Your Doctor Should Know

The Study of Women’s Health Across the Nation, known as SWAN, is the largest and most rigorous longitudinal investigation of the menopausal transition ever conducted. Over 3,000 women across five ethnic groups, followed for more than 20 years at five clinical centers. It remains the definitive dataset on what actually happens to women’s bodies during this transition [1].

Here is what SWAN found about bone:

During the premenopausal and early perimenopausal years, bone mineral density barely changes. The skeleton is stable. Then, in the late perimenopause, bone loss accelerates dramatically. In the lumbar spine, women lose 1.8 to 2.3% per year. In the hip, 1.0 to 1.4% per year [1].

These are not small numbers.

If that rate continues for five years, and it often does, the average woman’s spine loses 7 to 10% of its mineral density. The hip loses 5 to 7%. Those losses translate directly into fracture risk: a 50 to 100% increase [1].

More recent SWAN analyses identified what researchers call the “transmenopause,” a critical 3-year window spanning from one year before the final menstrual period to two years after it. During this window, White women lose an average of 2.5% per year in the lumbar spine and 1.8% per year in the femoral neck. Before this window, there is no appreciable bone loss at either site [2].

The Endocrine Society estimates that up to 20% of a woman’s total bone mass can be lost during the menopausal transition [3]. Women lose approximately 50% of their trabecular bone and 30% of their cortical bone over a lifetime, and roughly half of that loss occurs in the first 10 years after menopause [1].

The average age of perimenopause onset is 47.5 years [4]. The average age of menopause in the United States is 51. The rapid bone loss phase begins around age 50 for most women.

The USPSTF recommends screening with DXA at age 65.

That is a 15-to-18-year gap between when bone loss begins and when anyone looks.

What the Guidelines Actually Say

In January 2025, the US Preventive Services Task Force updated its osteoporosis screening recommendation. The core advice has not changed since 2011 [5]:

Screen all women 65 and older with DXA. That’s a B recommendation, meaning moderate certainty of moderate net benefit.

For postmenopausal women younger than 65, the USPSTF recommends screening only if they are “at increased risk,” determined by a clinical risk assessment tool such as FRAX. That’s also a B recommendation [5].

For perimenopausal women, there is no recommendation at all. Not a recommendation against screening. Not insufficient evidence. Simply silence.

The problem is not that these guidelines are wrong. The problem is what they miss. A 48-year-old woman in late perimenopause who is losing 2.5% of her spinal bone density per year does not fit the screening algorithm. She is not postmenopausal. She is not 65. She has no fracture history. FRAX, which begins at age 40, was designed primarily to predict fractures in older postmenopausal populations. Its accuracy in younger women is moderate at best [5].

So the fastest period of bone loss in a woman’s life falls neatly into a guideline gap. The biology is screaming. The guidelines are silent.

The Numbers That Should Terrify Us

One in two White women will experience an osteoporotic fracture in their lifetime. For White women, the lifetime risk of hip fracture alone is 1 in 6. That is more common than a breast cancer diagnosis, which is 1 in 9 [6].

We screen aggressively for breast cancer starting at 40. We screen for osteoporosis starting at 65. The disease with the higher lifetime risk gets 25 fewer years of surveillance.

Hip fractures are not minor injuries. Mortality rates in the first year after a hip fracture range from 20 to 24% [7]. Only 30 to 40% of patients recover their previous level of function. One third of formerly independent, community-dwelling women end up in nursing homes within a year of the fracture [7]. The annual economic burden of osteoporotic fractures in the United States exceeds $17.9 billion [6].

And here is the number that should change practice: a 10% loss of bone mass in the hip results in a 2.5 times greater risk of hip fracture [8]. That 10% is not a hypothetical. It is what many women lose during the menopausal transition.

The 2025 USPSTF report itself acknowledges that 27.1% of women 65 and older have osteoporosis [5]. Which means more than one in four women already have the disease by the time we first look.

That is not early detection. That is late discovery.

Subscribe now

Know Your Numbers: What to Ask For and When

This is the “Know Your Numbers” part. The part your doctor may not volunteer.

1. Know Your FRAX Score

The Fracture Risk Assessment Tool is free and takes two minutes. You can calculate it yourself at frax.shef.ac.uk. It estimates your 10-year probability of a major osteoporotic fracture and a hip fracture using clinical risk factors alone, without a DXA scan [9].

The inputs: your age, sex, weight, height, prior fracture, parental hip fracture, smoking status, alcohol use, glucocorticoid use, rheumatoid arthritis, and secondary osteoporosis causes.

A 10-year major osteoporotic fracture risk of 9.3% or higher, which is the risk level of an average 65-year-old White woman, is the USPSTF benchmark at which DXA screening becomes recommended [5]. Many women in their late 40s and early 50s with even one or two risk factors will meet that threshold. They just have to know to check.

2. Request a Baseline DXA During Perimenopause

The official guideline says 65. But the USPSTF also says that postmenopausal women younger than 65 with risk factors should be screened. And the Menopause Society states that women with established risk factors for osteoporosis should consider bone density assessment starting at menopause [10].

Risk factors that warrant earlier screening: a parent who broke a hip, low body weight (under 127 pounds), current smoking, excessive alcohol, early menopause (before 45), prolonged amenorrhea before menopause, glucocorticoid use, rheumatoid arthritis, type 1 diabetes, or hyperthyroidism.

If you have any of these, request a DXA scan. If your provider says it’s not indicated, ask them to document their refusal. A baseline DXA at the onset of menopause gives you something invaluable: a starting point. Without it, you will never know how much bone you have lost until you have lost enough to fracture.

3. Know Your 25-Hydroxyvitamin D Level

The SWAN Bone Study found that women with serum 25(OH)D levels below 20 ng/mL had significantly increased fracture risk during the menopausal transition. Higher levels were associated with less bone loss [11].

The Institute of Medicine defines adequacy as 20 ng/mL or above. Many bone health experts recommend at least 30 ng/mL for optimal skeletal protection [12].

This is a simple blood test. You should know your number. If it is below 20, you are deficient and need aggressive supplementation. If it is between 20 and 30, there is evidence that you would benefit from supplementation. The daily recommendation for most adults is 600 to 800 IU of vitamin D3, but many bone health experts recommend 1,000 to 2,000 IU daily, especially during and after the menopausal transition.

4. Know Your Calcium Intake

Postmenopausal women need 1,200 mg of calcium daily. Premenopausal women need 1,000 mg. Most American women get about 600 mg from their diet [13].

Do not guess. Track it for three days. One cup of milk or yogurt provides about 300 mg. One cup of cooked kale about 180 mg. Fortified orange juice about 350 mg per cup.

If you are falling short, dietary sources are preferable to supplements. If supplements are needed, take no more than 500 to 600 mg at a time for better absorption, and take them with food.

5. Know Your Exercise Prescription

This is not “stay active.” This is specific.

SWAN data showed that women who increased their leisure-time physical activity from early perimenopause to late perimenopause had significantly slower rates of BMD loss [14]. The data support weight-bearing and resistance exercise, not just walking.

The specific prescription: weight-bearing impact exercise (walking, jogging, dancing, stair climbing) for at least 30 minutes most days, plus resistance training (targeting major muscle groups) at least two to three times per week. Balance training becomes increasingly important to prevent falls.

The Role of Hormone Therapy

This deserves direct language. Menopausal hormone therapy is the most effective intervention for preventing bone loss during the menopausal transition.

The Women’s Health Initiative demonstrated a 34% reduction in fracture risk with hormone therapy, even in women at low baseline risk [15]. The International Menopause Society’s 2024 White Paper describes MHT as “foundational” for bone health maintenance, particularly when initiated in early postmenopause and in women under 60 [16]. It reduces bone turnover, increases bone mineral density, and lowers fracture risk at all skeletal sites.

The FDA has approved estrogen therapy specifically for the prevention of osteoporosis in postmenopausal women.

Yet many women who would benefit from hormone therapy during the critical bone loss window are never offered it. And many physicians, still operating under outdated fears from the early WHI interpretation, actively discourage it. The result: women lose bone during the exact years when the most effective prevention exists, and are told to wait for a DXA scan 15 years later.

Hormone therapy is not appropriate for every woman. But the conversation about its bone-protective effects should happen with every woman entering the menopausal transition. Waiting until 65 to discuss bone health means the opportunity for prevention has already passed.

This Is Not Conservative Medicine

Let me be clear about what we are doing.

We know that bone loss accelerates dramatically in the late perimenopause. The SWAN study has documented this across more than 2,000 women over more than two decades. The biology is not in dispute.

We know that the rapid bone loss phase begins, on average, around age 50 and spans a critical 3-year window around the final menstrual period. We know that by the time most women are screened at 65, up to 20% of their bone mass may already be gone.

We know that hip fractures kill 20 to 24% of women in the first year. We know that the lifetime risk of hip fracture in White women exceeds the lifetime risk of breast cancer. We know that a 10% loss of bone in the hip more than doubles fracture risk.

We know that FRAX is free and takes two minutes. We know that vitamin D levels are a simple blood test. We know that DXA is a low-cost, low-radiation scan that takes 15 minutes. We know that hormone therapy reduces fracture risk by a third, that bisphosphonates reduce vertebral fractures by half, and that exercise during perimenopause slows bone loss.

We know all of this.

And we wait until 65.

We do not wait until 65 to screen for breast cancer. We do not wait until 65 to check cholesterol. We do not wait until 65 to monitor blood pressure or blood sugar. For every other major chronic disease, we screen during the years when intervention can change the trajectory. For osteoporosis, we screen after the trajectory is set.

This is not careful medicine. This is not conservative medicine. This is the medical system choosing, year after year, to let women lose bone in the dark.

It does not have to be this way. You can calculate your FRAX score today. You can ask for a vitamin D level at your next visit. You can request a baseline DXA when you enter the menopausal transition. You can start the conversation about hormone therapy before the window closes.

Your bones are not waiting until 65. Your doctors should not be either.

If this post changed how you think about bone health, share it with a friend who is in her 40s or 50s. This is the information that should be in every gynecologist’s office, and it is not.

Subscribe to ObGyn Intelligence for evidence-based women’s health that challenges the status quo.

References

1. Finkelstein JS, Brockwell SE, Mehta V, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab. 2008;93(3):861-868.

2. Karlamangla AS, Burnett-Bowie SM, Engelman CD, et al. Bone health during the menopause transition and beyond. Obstet Gynecol Clin North Am. 2018;45(4):695-708.

3. Endocrine Society. Menopause and Bone Loss. Endocrine Society Patient Education. 2022.

4. Gold EB. The timing of the age at which natural menopause occurs. Obstet Gynecol Clin North Am. 2011;38(3):425-440.

5. US Preventive Services Task Force. Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement. JAMA. 2025;333(6):498-509.

6. International Osteoporosis Foundation. Epidemiology of osteoporosis and fragility fractures. IOF Facts and Statistics. Updated 2024.

7. Vidal EI, Moreira-Filho DC, Pinheiro RS, et al. Mortality after osteoporotic hip fracture: incidence, trends, and associated factors. J Orthop Surg Res. 2019;14(1):202.

8. Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15(4):721-739.

9. Schini M, Johansson H, Harvey NC, et al. An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis. J Endocrinol Invest. 2024;47(3):501-511.

10. The North American Menopause Society. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause. 2021;28(9):973-997.

11. Cauley JA, Greendale GA, Ruppert K, et al. Serum 25 hydroxyvitamin D, bone mineral density and fracture risk across the menopause. J Clin Endocrinol Metab. 2015;100(5):2046-2054.

12. Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84(1):18-28.

13. National Institutes of Health Office of Dietary Supplements. Calcium: Fact Sheet for Health Professionals. Updated 2024.

14. Greendale GA, Huang MH, Cauley JA, et al. Leisure time physical activity and bone mineral density preservation during the menopause transition and postmenopause: the SWAN study. Lancet Reg Health Am. 2023;20:100481.

15. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA. 2003;290(13):1729-1738.

16. Panay N, Anderson RA, Engel J, et al. Menopause and MHT in 2024: addressing the key controversies. An International Menopause Society White Paper. Climacteric. 2024;27(5):441-457.

She sits on the exam table in a paper gown and says, “I’ve missed four periods. Something is off.”

Her gynecologist orders a pregnancy test. Negative. Then a TSH. Normal. Then a CBC. Normal. Then an FSH.

The FSH comes back at 38 mIU/L. The gynecologist calls her and says it’s “borderline.” Come back in three months. We’ll recheck it.

She hangs up the phone confused. She still has no diagnosis. She still has no explanation. She still has no treatment plan. She has a follow-up appointment twelve weeks away for a repeat blood test that will tell her gynecologist nothing useful.

Here is what should have happened.

Her gynecologist should have looked at a 48-year-old woman who has missed four periods and said: “You are in the menopausal transition. This is a clinical diagnosis. I don’t need a blood test to tell you that. Let me explain what is happening in your body and what your options are.”

That visit should have taken fifteen minutes. Instead it will take six months, two office visits, four blood draws, and a co-pay she shouldn’t have had to pay.

Menopause Is a Clinical Diagnosis. Full Stop.

The international gold standard for staging reproductive aging is the STRAW+10 system, published in 2012 by a multidisciplinary consensus group of scientists from five countries, sponsored by the National Institutes of Health, the North American Menopause Society (now The Menopause Society), the American Society for Reproductive Medicine, the International Menopause Society, and the Endocrine Society [1].

STRAW+10 defines the stages of reproductive aging based on menstrual cycle patterns. The criteria are straightforward:

The early menopausal transition (Stage -2) is defined by a persistent difference of seven or more days in the length of consecutive menstrual cycles. The late menopausal transition (Stage -1) is defined by an interval of amenorrhea of 60 days or more. Menopause itself (Stage 0) is defined retrospectively as 12 consecutive months without a menstrual period [1].

A 48-year-old woman who has missed four periods has, by definition, experienced at least 60 days of amenorrhea. She is in the late menopausal transition. This is not a matter of clinical judgment. It is not ambiguous. It is not borderline. It is the textbook definition of Stage -1.

STRAW+10 was designed to be applied regardless of age, ethnicity, body size, or lifestyle characteristics [1]. It is the Marshall-Tanner staging of reproductive aging. Every gynecologist in training should know it the way they know Bishop scores and Apgar scores.

Most don’t.

The FSH Test Your Doctor Ordered Is Useless

Here is something every patient should know and every physician was apparently never taught: FSH is not recommended for diagnosing menopause in women 45 and older.

The UK’s National Institute for Health and Care Excellence updated its menopause guideline in November 2024. The first quality statement reads: “Women aged 45 or over who present with menopausal symptoms are diagnosed with perimenopause or menopause based on their symptoms alone, without confirmatory laboratory tests” [2].

Not “consider” diagnosing without labs. Not “may” diagnose without labs. Diagnose. Without. Labs.

NICE explicitly instructs clinicians: “Do not use the following laboratory and imaging tests to identify perimenopause or menopause in people aged 45 or over” [2]. The list includes FSH, anti-Mullerian hormone, inhibin A and B, estradiol, and ovarian ultrasound.

Why? Because FSH fluctuates enormously during perimenopause. A single FSH value can be 15 one week and 55 the next in the same woman. As NICE states, hormone levels “fluctuate during the perimenopause” and “knowing these levels will not change management” [3]. ACOG agrees. The Menopause Society agrees. The British Menopause Society agrees.

When a 2017 paper in the Annals of Clinical Biochemistry reviewed the evidence behind the NICE guideline, the authors were blunt: “Reducing the number of unnecessary FSH tests in women over 45 is an area of care where considerable savings could be made through disinvestment” [4]. They weren’t talking about cutting corners. They were talking about eliminating a test that adds cost, delays diagnosis, and provides no clinically useful information.

Your gynecologist’s FSH order wasn’t cautious medicine. It was uninformed medicine.

Why Your Doctor Doesn’t Know This

The answer is simple and infuriating: nobody taught them.

A 2023 survey of 99 U.S. OB/GYN residency program directors found that only 31.3% reported having a menopause curriculum in their training program. Nearly all of them, 92.9%, agreed that residents nationwide should have access to a standardized menopause curriculum [5]. They know the gap exists. They endorse closing it. They haven’t closed it.

Only 20% of OB/GYN residencies offer dedicated menopause training [6]. One in five family medicine, internal medicine, and OB/GYN residents reported receiving zero menopause lectures during their entire residency [7]. And only 6.8% of residents felt adequately prepared to manage women experiencing menopause [7].

A global review published in Best Practice & Research Clinical Obstetrics & Gynaecology examined menopause medical education across countries and concluded that training on menopause management is “profoundly inadequate even nowadays” [8].

Think about what these numbers mean in practical terms. A woman who has completed medical school and a four-year OB/GYN residency, passed her board examinations, and hung a diploma on her wall may never have been taught how to diagnose menopause. Not the nuances of managing complex menopausal symptoms. Not the subtleties of hormone therapy prescribing. The diagnosis itself. The STRAW+10 criteria. The fact that it’s clinical. The fact that you don’t order an FSH.

She wasn’t taught it in medical school. She wasn’t taught it in residency. She wasn’t tested on it for boards. And now she is the physician sitting across from a 48-year-old woman who has missed four periods and doesn’t know what to say.

What This Costs Women

The consequences of this diagnostic incompetence are not abstract.

When a gynecologist cannot diagnose the menopausal transition, the patient leaves without answers. She Googles her symptoms at midnight. She finds terrifying articles about premature ovarian failure, thyroid disease, and early-onset dementia. She doesn’t sleep. She makes another appointment, this time with her primary care doctor, who orders the same labs again.

When a gynecologist cannot diagnose the menopausal transition, the patient doesn’t get treatment. She doesn’t learn that her hot flashes, her disrupted sleep, her joint pain, her vaginal dryness, her mood changes, and her irregular bleeding all have the same underlying cause. Each symptom gets its own workup, its own referral, its own medication. A sleep study for the insomnia. An antidepressant for the mood changes. A urology referral for the urinary symptoms. A rheumatology referral for the joint pain. None of these specialists diagnose the menopause transition either, because none of them were trained to.

When a gynecologist cannot diagnose the menopausal transition, the patient loses time. The average woman spends the late menopausal transition, the period between skipping cycles and her final menstrual period, in that stage for one to three years [1]. If her physician doesn’t recognize where she is in that trajectory, she spends those years undertreated or untreated entirely.

And when a gynecologist cannot diagnose the menopausal transition, the patient loses trust. She walked into the office of the physician who is supposed to be the expert on her reproductive health and that physician could not identify the single most predictable event in reproductive aging. Why would she trust that physician with anything else?

The Absurdity of the Situation

Let me put this in perspective.

If a 13-year-old girl walks into a pediatrician’s office and says she got her first period, no one orders a blood test to confirm it. No one checks her estradiol to make sure puberty is real. No one says, “Your menarche is borderline. Let’s recheck in three months.” The pediatrician says, “Congratulations, you’re going through puberty. Here’s what to expect.”

Menopause is the other bookend of reproductive life. It is equally universal, equally predictable, and equally diagnosable on clinical grounds. The STRAW+10 system was explicitly designed to be the reproductive aging equivalent of the Marshall-Tanner pubertal staging system [1]. Yet we treat one as obvious and the other as a diagnostic mystery requiring laboratory confirmation.

The difference is not scientific. The difference is that we invested in teaching physicians about the beginning of reproductive life and decided the end of it wasn’t worth their time.

What You Should Know

If you are 45 or older and your periods have become irregular, here is what the evidence supports:

You do not need an FSH test to know what is happening. If your cycles have become unpredictable, if you are skipping periods, if you have gone 60 or more days without bleeding, you are in the menopausal transition. This is a clinical diagnosis based on your menstrual pattern. Every major guideline in the world says the same thing [1, 2, 3].

An FSH level will not help you or your doctor. FSH swings wildly during perimenopause. A “normal” FSH does not mean you are not in the menopausal transition. An “elevated” FSH does not tell your doctor anything your menstrual history didn’t already say. If your physician orders an FSH when you are over 45 with irregular periods, your physician is not practicing evidence-based medicine.

You deserve a diagnosis at the first visit. A 48-year-old woman with four missed periods should leave her gynecologist’s office with a diagnosis, an explanation, and a plan. Not a lab slip and a follow-up in three months. If your physician cannot provide that, you have the right to ask why, and the right to find one who can.

“Too young” is not a medical assessment. The median age of menopause in the United States is 51, but the menopausal transition commonly begins in the mid-40s. The late menopausal transition, Stage -1, lasts one to three years before the final menstrual period [1]. A woman experiencing cycle changes at 45, 46, 47, or 48 is not “too young.” She is exactly on time.

Your symptoms are connected. The hot flashes, the sleep disruption, the mood changes, the vaginal dryness, the joint aches, the irregular bleeding: these are not separate problems requiring separate specialists. They are manifestations of a single hormonal transition. A physician who understands menopause can address them together. A physician who doesn’t will scatter you across the healthcare system chasing symptoms instead of treating causes.

This Is Our Failure

I am a gynecologist. I am writing this because this is our profession’s failure, and we need to own it.

Menopause is not a rare disease. It is not a niche interest. It is a universal biological event that every woman who lives long enough will experience. It affects bone density, cardiovascular risk, urogenital health, sexual function, sleep, mood, and cognition. It lasts, in its full symptomatic arc, for years.

And we graduate physicians who cannot diagnose it in a straightforward clinical presentation.

The STRAW+10 criteria have been published since 2012. The NICE guideline has said not to order FSH in women over 45 since 2015, and reaffirmed it in 2024. The Menopause Society has recommended clinical diagnosis for years. This is not new science waiting for translation. This is old science that the medical education system never bothered to teach.

Only 31% of OB/GYN residency programs have a menopause curriculum [5]. That means 69% are graduating gynecologists without structured training in a condition that affects 100% of their female patients.

We have no trouble teaching residents to diagnose preeclampsia. We have no trouble teaching them to manage postpartum hemorrhage. We have no trouble teaching them to stage cervical cancer. But the menopausal transition, the transition that every single one of their patients will go through, somehow didn’t make the cut.

Until residency programs require menopause education, until board exams weight it appropriately, until physicians are held accountable for knowing the diagnostic criteria for the most common endocrine transition in women’s health, women will keep sitting on exam tables in paper gowns, asking obvious questions, and getting blood draws instead of answers.

That is not a knowledge gap. That is a professional failure.

If this post made you angry, good. Share it with your doctor. Share it with your friends. Subscribe to ObGyn Intelligence for evidence-based women’s health that holds the profession accountable.

References

1. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97(4):1159-1168.

2. National Institute for Health and Care Excellence. Menopause: identification and management. NICE guideline [NG23]. Updated November 2024.

3. NICE Quality Standards. Quality statement 1: Diagnosing perimenopause and menopause. QS143. Updated 2024.

4. Davies M, Sarri G, Lumsden MA. Diagnosis of the menopause: NICE guidance and quality standards. Ann Clin Biochem. 2017;54(3):326-330.

5. Allen JT, et al. Needs assessment of menopause education in United States obstetrics and gynecology residency training programs. Menopause. 2023;30(10):999-1005.

6. Cuyuna Regional Medical Center. Addressing the Knowledge Gap: Menopause. January 2025.

7. The Menopause Society. Menopause Step-by-Step educational initiative; reported in The Flow Space, August 2024.

8. Armeni E, Paschou SA, Gkika I, et al. Menopause medical education around the world: the way forward to serve women’s health. Best Pract Res Clin Obstet Gynaecol. 2022;81:44-59.

Not obscure words. Words she had used in depositions for twenty years. She would stand in front of a judge and reach for a term she had deployed a thousand times and find nothing. A blank. A gap where language used to be.

She went to her primary care physician. He told her she was stressed. She went to her gynecologist. The gynecologist ordered basic labs and said everything looked normal. She asked about menopause. The gynecologist said she was “too young.”

She Googled “memory loss at 47” at 2 a.m. and spent an hour reading about early-onset Alzheimer’s disease. She didn’t sleep that night. Or the next.

Nobody told her that what she was experiencing had a name, a mechanism, and for most women, a resolution. Nobody told her because her doctors didn’t know.

The Fear Nobody Addresses

Here is what happens in exam rooms across the country every day: a woman in her mid-to-late 40s describes difficulty concentrating, word-finding problems, trouble with multitasking she used to handle effortlessly, and a general sense that her brain is not working the way it used to. She is terrified.

She is terrified because women account for nearly two-thirds of Alzheimer’s diagnoses. She is terrified because she watched her mother or grandmother disappear into dementia. She is terrified because every article about “cognitive decline” in midlife reads like a death sentence.

And her doctor, more often than not, does one of three things: orders a basic cognitive screening test that she passes easily, attributes her symptoms to stress or depression, or shrugs and says there is nothing to be done.

What the doctor almost never does is say: “What you’re experiencing is a well-documented phenomenon of the menopause transition. It has been studied in large longitudinal cohorts. For most women, it resolves. Let me explain what’s happening in your brain and what you can do about it.”

The doctor doesn’t say this because the doctor was never taught it.

What the Science Actually Shows

The largest and most rigorous longitudinal data on cognition during the menopause transition comes from the Study of Women’s Health Across the Nation, known as SWAN. This study followed 2,362 women with serial cognitive testing over multiple years and found something important: perimenopause is associated with a transient decrement in processing speed and verbal memory [1].

The word “transient” matters enormously.

The SWAN findings showed that during late perimenopause, women stopped showing the expected improvement on repeated cognitive tests. In middle-aged adults, when you give the same test multiple times, scores normally get better because of practice effects. During perimenopause, that learning stopped. Then, after menopause, the learning curve resumed [1, 2].

This is not the pattern of a degenerative disease. This is the pattern of a system in transition.

The Penn Ovarian Aging Study followed 403 women over 14 years and found a similar picture: difficulties in verbal memory during perimenopause that resolved in postmenopause, though some challenges with verbal learning persisted longer [3]. Dr. Pauline Maki, one of the foremost researchers in this field, published a clinical guide in Climacteric in 2022 summarizing the evidence: cognitive complaints during menopause are real and measurable, they emerge when menstrual cycles become irregular, they commonly normalize after menopause, and they are not an early phase of a dementing disorder [4].

About 60% of women going through the menopause transition report memory problems. But when formally tested, most remain within the normal cognitive range. About 11 to 13% show clinically significant impairment [4]. That means the vast majority of women experiencing brain fog are experiencing a normal, time-limited neurological event, not the beginning of the end.

Your Brain Is Remodeling, Not Declining

In 2021, neuroscientist Lisa Mosconi and her team at Weill Cornell Medicine published a landmark study in Scientific Reports that changed how we understand the menopausal brain. Using PET and MRI brain imaging on 161 women across premenopausal, perimenopausal, and postmenopausal stages (with age-matched male controls), they documented substantial differences in brain structure, connectivity, and energy metabolism across the menopause transition [5].

Here is what they found: during perimenopause, there is a measurable dip in gray matter volume, white matter volume, and glucose metabolism in the brain. The brain’s primary fuel source becomes less efficient. This correlates exactly with the symptoms women describe: the fog, the word-finding difficulty, the sensation that thinking requires more effort than it should.

But here is the part that should be in every physician’s talking points: when the team followed postmenopausal participants, brain biomarkers largely stabilized. Gray matter volume recovered in key regions involved in cognitive aging [5]. The brain compensated for declining estrogen by increasing cerebral blood flow and shifting to alternative energy pathways.

Mosconi described this as a brain in “remodeling,” comparing it to a machine that once ran on gas and is now switching to electricity [6]. The transition period is rough. The destination is functional.

This distinction matters because the narrative women encounter on social media is catastrophic. Viral claims that the menopausal brain “literally eats itself” without hormone therapy are not supported by the evidence. They are marketing dressed as neuroscience. And they drive terrified women toward unregulated products promising to rescue their “degenerating” brains.

The Lancet Just Settled a Major Question

In December 2025, The Lancet Healthy Longevity published the most comprehensive systematic review and meta-analysis to date on hormone therapy and dementia risk. Commissioned by the World Health Organization, it analyzed data from over one million participants across 10 studies [7].

The conclusion: no significant association between menopause hormone therapy and the risk of dementia or mild cognitive impairment. Not protective. Not harmful. Neutral.

Subgroup analyses found no evidence for a “critical window” of timing. Starting hormone therapy between ages 45 and 55 did not reduce dementia risk. Using it for less than five years, between five and ten years, or longer than ten years showed no consistent effect in either direction [7, 8].

This matters for two reasons.

First, it takes dementia fear off the table for women considering hormone therapy for menopausal symptoms. The FDA’s now-removed black box warning had included language about increased dementia risk, which was based on the Women’s Health Initiative Memory Study, a trial that enrolled women at an average age of 65. That finding was never applicable to women starting hormone therapy at menopause, and the Lancet review confirms it: no evidence of increased risk [7].

Second, it reins in the opposite overclaim. Hormone therapy should not be prescribed specifically to prevent dementia. The data don’t support it. The Lancet Commission on Dementia Prevention, the UK’s NICE guidelines, and now this WHO-commissioned review all agree: hormone therapy decisions should be guided by symptom management and individual risk-benefit assessment, not by promises of cognitive protection that the evidence doesn’t substantiate [7, 9].

This is what evidence-based medicine looks like. Not fear. Not false promises. Honest data, honestly communicated.

The Training Gap That Makes All of This Worse

Here is where the story becomes a professional accountability problem.

A 2023 survey of 99 U.S. OB/GYN residency program directors found that only 31.3% reported having a menopause curriculum in their program. Meanwhile, 92.9% of those same program directors agreed that residents nationwide should have access to a standardized menopause curriculum [10]. They know the training is missing. They just haven’t built it.

Only 20% of OB/GYN residencies offer dedicated menopause training [11]. One in five family medicine, internal medicine, and OB/GYN residents reported receiving no menopause lectures during residency. Not inadequate lectures. Zero [12]. And only 6.8% of residents felt adequately prepared to manage women experiencing menopause [12].

A global review published in Best Practice & Research Clinical Obstetrics & Gynaecology concluded that training on menopause management is “profoundly inadequate even nowadays” [13].

Think about this: approximately 1.1 billion women worldwide are menopausal. The physicians responsible for their care are being trained in programs where menopause is, at best, an afterthought. A woman walks in with brain fog at age 48 and her gynecologist, who completed four years of residency focused largely on pregnancy and surgery, may genuinely not know that the SWAN study exists. May not know about neural remodeling. May not know the Lancet data. May not know that the right answer is: “This is normal, it’s temporary for most women, and here’s what we can do.”

Instead, the physician orders a depression screening or a thyroid panel and moves on.

What’s Actually Driving the Fog

The cognitive changes of perimenopause aren’t random. They have identifiable drivers, and some of them are treatable:

Estrogen withdrawal. Estrogen receptors are densely concentrated in the hippocampus and prefrontal cortex, the brain regions responsible for memory and executive function. When estrogen fluctuates wildly and then drops, these regions are directly affected [5, 14]. This is not a vague hormonal theory. It has been visualized on brain scans.

Sleep disruption. Night sweats fragment sleep architecture. Poor sleep directly impairs memory consolidation, attention, and executive function. Many women experiencing “brain fog” are actually experiencing the cognitive consequences of months or years of disrupted sleep [15].

Vasomotor symptoms. Hot flashes are not just uncomfortable. Objectively measured hot flashes (as opposed to self-reported ones) have been associated with worse verbal memory performance [4]. The thermoregulatory disruption itself may affect brain function.

Mood changes. Depression and anxiety, both more common during the menopause transition, independently impair cognitive processing speed and verbal memory [2].

This means that treating the treatable components, managing vasomotor symptoms, addressing sleep disruption, treating depression and anxiety, can meaningfully improve cognitive function. Not because these treatments fix the brain fog directly, but because they remove the factors compounding it.

What You Should Know

If you are in your mid-40s to mid-50s and experiencing cognitive changes, here is what the evidence supports:

Your brain is not degenerating. The cognitive changes of perimenopause are well-documented, time-limited for most women, and reflect a brain in transition, not in decline. The SWAN study, the Penn Ovarian Aging Study, and Mosconi’s neuroimaging work all point in the same direction: this is temporary.

You probably don’t need a dementia workup. Alzheimer’s disease is rare in women under 60. If your cognitive complaints began around the time your periods became irregular, the most likely explanation is the menopause transition, not neurodegeneration. If you are concerned, formal neuropsychological testing can distinguish between perimenopause-associated cognitive changes and early dementia far better than a screening questionnaire.

Hormone therapy may help your symptoms, but not through the brain. The strongest evidence for cognitive improvement with hormone therapy is indirect: by reducing hot flashes and improving sleep, it addresses the factors that are worsening your cognition. Don’t take hormone therapy specifically for “brain protection.” That’s not what the data show.

Lifestyle interventions matter. Aerobic exercise, sleep hygiene, stress management, and social engagement all have evidence supporting their role in cognitive function during the menopause transition. These are not consolation prizes. They are interventions that target the same pathways affected by estrogen withdrawal.

Be skeptical of anyone selling you brain rescue. If a product claims to “treat cognitive decline during menopause” or prevent your brain from “eating itself,” ask for the randomized trial. If there isn’t one, you’re being marketed to, not treated.

The Professional Failure

There is no excuse for the training gap. Menopause is not a rare condition. It is not a niche interest. It is a universal biological event affecting half the population, with well-characterized effects on cognition, bone, cardiovascular health, urogenital function, and mental health. The idea that a physician can complete a four-year OB/GYN residency without a structured menopause curriculum and then take care of women for the next thirty years is not a gap. It is a failure of professional education.

The data are here. The SWAN study has been publishing for over two decades. Maki’s clinical guide for health professionals has been available since 2022. The Lancet review was commissioned by the WHO. This is not emerging science. It is established science that the medical education system has failed to teach.

Every woman going through perimenopause deserves a physician who can look her in the eye and say: “Your brain fog is real. It’s not dementia. Here’s what’s happening and here’s what we can do.” That this remains the exception rather than the rule is a problem we created, and one we can fix.

If this changed how you understand what’s happening to your brain, share it with a friend who needs to hear it. Subscribe to ObGyn Intelligence for evidence-based women’s health without the fear.

References

1. Greendale GA, Huang MH, Wight RG, et al. Effects of the menopause transition and hormone use on cognitive performance in mid-life women. Neurology. 2009;72(21):1850-1857.

2. Greendale GA, Wight RG, Huang MH, et al. Menopause-associated symptoms and cognitive performance: results from the Study of Women’s Health Across the Nation. Am J Epidemiol. 2010;171(11):1214-1224.

3. Epperson CN, Sammel MD, Freeman EW. Menopause effects on verbal memory: findings from a longitudinal community cohort. J Clin Endocrinol Metab. 2013;98(9):3829-3838.

4. Maki PM, Jaff NG. Brain fog in menopause: a health-care professional’s guide for decision-making and counseling on cognition. Climacteric. 2022;25(6):570-578.

5. Mosconi L, Berti V, Dyke J, et al. Menopause impacts human brain structure, connectivity, energy metabolism, and amyloid-beta deposition. Sci Rep. 2021;11:10867.

6. Mosconi L. The Menopause Brain: New Science Empowers Women to Navigate the Pivotal Transition with Knowledge and Confidence. Avery; 2024.

7. Melville M, He L, Desai R, et al. Menopause hormone therapy and risk of mild cognitive impairment or dementia: a systematic review and meta-analysis. Lancet Healthy Longev. 2025;6(12):100803.

8. University College London. Menopause hormone therapy does not appear to impact dementia risk. UCL News. December 22, 2025.

9. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572-628.

10. Allen JT, et al. Needs assessment of menopause education in United States obstetrics and gynecology residency training programs. Menopause. 2023;30(10):999-1005.

11. Cuyuna Regional Medical Center. Addressing the Knowledge Gap: Menopause. January 2025.

12. The Flow Space. Most medical schools lack menopause training. August 29, 2024.

13. Armeni E, Paschou SA, Gkika I, et al. Menopause medical education around the world: the way forward to serve women’s health. Best Pract Res Clin Obstet Gynaecol. 2022;81:44-59.

14. Metcalf CA, Duffy KA. Cognitive problems in perimenopause: a review of recent evidence. Curr Psychiatry Rep. 2023;25(10):501-511.

15. Weber MT, Maki PM, McDermott MP. Cognition and mood in perimenopause: a systematic review and meta-analysis. J Steroid Biochem Mol Biol. 2014;142:90-98.

But she had stopped having sex with her husband.

Not because she didn’t want to. Because it felt like being cut with glass. Vaginal dryness so severe that even a pelvic exam made her cry. She had recurrent urinary tract infections, three in six months, each one treated with antibiotics that gave her a yeast infection that made the dryness worse.

Her oncologist told her estrogen was off the table. “You had breast cancer. We can’t risk it.”

Her gynecologist handed her a pamphlet about lubricants.

Nobody told her about vaginal estrogen. Or if they knew about it, they were too afraid to prescribe it.

She is not unusual. She is the norm.

What Vaginal Estrogen Actually Is

Let’s start with what we’re talking about, because the word “estrogen” makes people panic.

Vaginal estrogen is a low-dose, locally applied hormone. It comes as a cream, a tablet, a ring, or a soft gel insert. It is placed directly in the vagina. It works on the vaginal and urethral tissues. That’s it.

It is not systemic hormone therapy. It does not circulate through your body the way a pill or a patch does. The doses are tiny. A standard vaginal estrogen tablet delivers 10 micrograms of estradiol. For perspective, a systemic hormone therapy pill delivers 500 to 2,000 micrograms. We are talking about a fraction of a fraction.

Multiple studies using sensitive assays have confirmed that low-dose vaginal estrogen does not raise serum estradiol levels above normal postmenopausal ranges [1]. The estrogen stays local. It restores the vaginal tissue, the urethral lining, and the bladder trigone. It goes where it’s needed and does not go where it isn’t.

The Condition Nobody Talks About

Genitourinary syndrome of menopause, or GSM, affects between 27% and 84% of postmenopausal women [2]. The range is that wide because most women never bring it up, and most doctors never ask.

GSM is not “just dryness.” It is a progressive condition driven by estrogen loss that affects the entire lower genitourinary tract. The vaginal walls thin. The tissue loses elasticity. The pH rises. Lactobacilli disappear. The vaginal microbiome shifts toward organisms that cause infection. The urethral lining thins. The bladder trigone loses its cushion.

The symptoms are devastating: vaginal burning, itching, pain with sex, pain with pelvic exams, urinary urgency, frequency, incontinence, and recurrent UTIs. Unlike hot flashes, which tend to improve over time, GSM gets worse without treatment [3]. Every year without estrogen, the tissue degrades further.

And here is the part that should make every physician uncomfortable: we have an effective, safe, cheap treatment. We’ve had it for decades. And millions of women aren’t getting it.

The Black Box That Wasn’t Based on Science

Every estrogen product in the United States, until late 2025, carried the same FDA black box warning. Vaginal estrogen tablets. Systemic hormone pills. The same warning. The same language about stroke, blood clots, breast cancer, and dementia.

This made no pharmacological sense.

A 10-microgram vaginal tablet that doesn’t raise systemic estrogen levels carried the same warning as a systemic pill that delivers 100 times the dose to every organ in the body. It was the regulatory equivalent of putting a liver failure warning on a glass of orange juice because tequila can damage your liver. Both contain liquid. That’s where the similarity ends.

The black box warning originated from the Women’s Health Initiative findings in the early 2000s, which studied systemic hormone therapy in women whose average age was 63. Those findings, whatever their merits for systemic therapy, had nothing to do with vaginal estrogen. But the FDA applied class labeling: if the molecule was an estrogen, it got the warning.

In July 2025, an FDA advisory panel convened to review these warnings. Expert after expert testified that the vaginal estrogen label was not supported by evidence. Dr. JoAnn Pinkerton presented meta-analysis data showing no increased cancer recurrence in breast cancer survivors using vaginal estrogen. Dr. James Simon pointed out that a 4-microgram vaginal estrogen product carried the same warnings as high-dose systemic therapy despite being pharmacologically incapable of affecting distant organs. Dr. Monica Christmas called the warning “overstated” [4].

In November 2025, the FDA finally removed the black box warnings from all estrogen products [5]. Two decades late.

What the Evidence Actually Shows

Let’s look at the data that was available for years while women suffered:

Cancer recurrence in breast cancer survivors. A 2024 JAMA Oncology study followed 49,237 women with breast cancer. Those who used vaginal estrogen had no increase in breast cancer-specific mortality compared to those who used no hormone therapy. In fact, the hazard ratio was 0.77, meaning vaginal estrogen users actually trended toward better survival [6].

A 2025 AJOG meta-analysis by Beste et al. confirmed: vaginal estrogen in breast cancer survivors showed no increased risk of recurrence, cancer-specific mortality, or overall mortality [7].

A 2025 meta-analysis in the Brazilian Journal of Gynecology and Obstetrics reached the same conclusion: vaginal estrogen may be considered safe in women with a history of breast cancer, with minimal systemic absorption and no increase in mortality or recurrence [8].

UTI prevention. Systematic reviews demonstrate that vaginal estrogen reduces recurrent UTIs in postmenopausal women. It restores the vaginal microbiome, lowers pH, and rebuilds the urethral and bladder lining that serves as a barrier against infection [9]. Every course of antibiotics we prescribe for a postmenopausal UTI, when the underlying cause is estrogen deficiency, is treating the symptom and ignoring the disease.

Urinary symptoms. Vaginal estrogen improves urgency, frequency, stress incontinence, and urge incontinence. The estrogen receptors in the bladder trigone and urethra respond to local therapy [10].

Endometrial safety. Endometrial hyperplasia and cancer are extremely rare with low-dose vaginal estrogen. The doses are too small to stimulate the endometrium, and unlike systemic therapy, vaginal estrogen generally does not require a progestogen for endometrial protection [11].

Who Wasn’t Prescribing It, and Why

The fear wasn’t just about the label. It was about medical culture.

Oncologists, understandably cautious about anything with the word “estrogen” in breast cancer survivors, told patients it was contraindicated. Many still do, despite ACOG, the Menopause Society, and the International Society for the Study of Women’s Sexual Health all publishing consensus statements saying vaginal estrogen can be considered when non-hormonal treatments fail [12].

Primary care physicians, most of whom received minimal menopause training in residency, saw the black box and assumed the risk was real. They defaulted to lubricants and moisturizers. These products provide temporary symptom relief but do nothing to address the underlying tissue atrophy. It’s like giving chapstick for a chemical burn.

Gynecologists who knew the data still hesitated. Prescribing a drug with a black box warning creates liability exposure. Charting “discussed risks and benefits of vaginal estrogen including the FDA black box warning regarding stroke, blood clots, and cancer” for a product that poses none of those risks was both absurd and required.

The result: a 2025 AUA/SUFU/AUGS guideline noted that despite GSM affecting up to 87% of postmenopausal women, the condition remains both underdiagnosed and undertreated [13]. The treatment exists. The evidence supports it. The guidelines recommend it. And women still aren’t getting it.

Subscribe now

The Real Cost

Count the costs of not prescribing vaginal estrogen:

Millions of postmenopausal women with painful sex who were told to try lubricant. Millions of courses of antibiotics for recurrent UTIs that could have been prevented. Emergency department visits for urosepsis in elderly women whose recurrent infections went unchecked. Marriages strained or ended because intimacy became impossible. Women who stopped going to the gynecologist because pelvic exams were too painful. Quality of life sacrificed on the altar of a warning label that had no scientific basis.

All because a bureaucratic decision to apply class labeling treated a local vaginal treatment the same as a systemic pill.

What You Should Know

If you are postmenopausal and experiencing vaginal dryness, painful sex, urinary urgency, frequency, or recurrent UTIs, ask your doctor about vaginal estrogen. Specifically:

The numbers that matter. Low-dose vaginal estrogen delivers 4 to 10 micrograms of estradiol locally. Serum levels remain within normal postmenopausal range. There is no demonstrated increased risk of breast cancer, stroke, blood clots, or heart disease at these doses.

If you are a breast cancer survivor. The largest studies show no increased recurrence or mortality with vaginal estrogen. Guidelines from ACOG, the Menopause Society, and the 2025 AUA guideline all support considering vaginal estrogen when non-hormonal options are insufficient. If your oncologist says “absolutely not,” ask them to cite the study showing harm. They won’t find one.

The alternatives are not equivalent. Lubricants reduce friction during sex. Moisturizers provide temporary hydration. Neither reverses the underlying tissue atrophy. Neither prevents UTIs. Neither restores the vaginal microbiome. They are band-aids. Vaginal estrogen treats the disease.

It’s not expensive. Generic vaginal estrogen cream and tablets are available. This is not a boutique treatment.

The Bigger Question

The FDA corrected the label. That matters. But it doesn’t answer the harder question: why did it take over 20 years?

The data on vaginal estrogen’s safety profile was not new in 2025. It was available in 2010. It was available in 2015. Professional societies published consensus statements years before the FDA acted. The evidence was there. The regulatory will was not.

In that gap, millions of women suffered symptoms that had an effective, safe, inexpensive treatment. Some of those women were your patients. Some of them were your mothers. Some of them were you.

The label is fixed. The culture hasn’t caught up yet.

If your doctor still hesitates to prescribe vaginal estrogen, show them this post. Show them the JAMA Oncology study. Show them the AJOG meta-analysis. Show them the FDA’s own decision.

And then ask them the question they should be asking themselves: if the evidence was this clear, why did anyone wait?

If this was helpful, share it with someone who needs it. Subscribe to ObGyn Intelligence for evidence-based women’s health, delivered without the hedging.

Subscribe now

References

1. Santen RJ, Mirkin S, Engel S, et al. Systemic estradiol levels with low-dose vaginal estrogens. Menopause. 2020;27(3):361-370.

2. Kagan R, Kellogg-Spadt S, Parish SJ. Genitourinary syndrome of menopause. StatPearls. Updated October 5, 2024.

3. The Menopause Society. MenoNote: Genitourinary Syndrome of Menopause. 2025.

4. Healio. FDA panel calls for label changes, more education on menopausal hormone therapy. July 17, 2025.

5. U.S. Department of Health and Human Services. Fact Sheet: FDA Initiates Removal of “Black Box” Warnings from Menopausal Hormone Replacement Therapy Products. November 10, 2025.

6. McVicker L, Labeit AM, Coupland CAC, et al. Vaginal estrogen therapy use and survival in females with breast cancer. JAMA Oncol. 2024;10(1):103-108.

7. Beste ME, Kaunitz AM, McKinney JA, Sanchez-Ramos L. Vaginal estrogen use in breast cancer survivors: a systematic review and meta-analysis of recurrence and mortality risks. Am J Obstet Gynecol. 2025;232(3):262-270.e1.

8. Santos GM, Magalhães AO, Teichmann PV, et al. Vaginal estrogen therapy for treatment of menopausal genitourinary syndrome among breast cancer survivors: a systematic review and meta-analysis. Rev Bras Ginecol Obstet. 2025;47:e-rbgo46.

9. Rahn DD, Carberry C, Sanses TV, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol. 2014;124(6):1147-1156.

10. AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause. J Urol. 2025.

11. International Menopause Society. Menopause and MHT in 2024: addressing key controversies. IMS White Paper. Climacteric. 2024.

12. Faubion SS, Larkin LC, Stuenkel CA, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations. Menopause. 2018;25(6):596-608.

13. UNC Department of Urology. New AUA Guideline on GSM highlights urology’s role in menopause care. July 11, 2025.

It’s a tidy story. But is it true?

The Problem Starts With the Name

“Anti-inflammatory diet” isn’t a medical term. There’s no definition in any clinical guideline or textbook. It’s a marketing label applied to whatever foods the author wants to sell you—usually some combination of salmon, berries, turmeric, and olive oil, with occasional detours into bone broth and adaptogenic mushrooms.

What does exist is research on the Mediterranean diet, which emphasizes fruits, vegetables, whole grains, fish, and olive oil. Multiple meta-analyses have examined whether this eating pattern reduces inflammatory markers like C-reactive protein (CRP) and interleukin-6 (IL-6).

The findings? Modest reductions in CRP averaging about 1 mg/L. Sounds impressive until you realize the studies show enormous variability (heterogeneity often exceeds 90%), meaning results are wildly inconsistent across trials. Some studies show big effects; others show none. The most recent systematic reviews note that “further high-quality studies will be essential to confirm these findings.”

And here’s the kicker: most of these trials weren’t done in menopausal women specifically. They studied mixed populations, often people with diabetes or heart disease.

What About Hot Flashes?

The best evidence for diet affecting menopausal symptoms comes from trials testing soy—not generic “anti-inflammatory” eating.

A 2021 randomized trial assigned 84 women with frequent hot flashes to either a low-fat vegan diet with half a cup of soybeans daily or no dietary changes. After 12 weeks, moderate-to-severe hot flashes dropped by 88% in the soy group versus 34% in controls. Impressive.

But let’s be clear about what this study tested: phytoestrogens from soy, not “anti-inflammatory” effects. Soy isoflavones are plant compounds that weakly mimic estrogen. They may help hot flashes through estrogen receptors, not by reducing inflammation.

A 2025 meta-analysis of soy isoflavone trials found they were not significantly effective for vasomotor symptoms overall. Some trials showed benefit; others didn’t. The results may depend on whether women can metabolize soy into equol (only about 30% of Westerners can).

In other words: the evidence for soy helping hot flashes is real but inconsistent. The evidence for “anti-inflammatory diets” broadly helping menopause symptoms is much weaker.

The Conflation Game

The wellness industry plays a sleight-of-hand trick here. They take three separate findings:

1. Mediterranean diet patterns are associated with lower inflammatory markers in some studies

2. Soy phytoestrogens may reduce hot flashes in some women

3. Healthier eating patterns are associated with better overall health

Then they blend these into one magical concept—the “anti-inflammatory diet for menopause”—as if the mechanisms are the same. They’re not.

Eating more vegetables and less processed food is sensible advice for everyone. Saying that specific foods “fight inflammation” to cure your hot flashes goes beyond what the science supports.

What Actually Works

For hot flashes, hormone therapy remains the most effective treatment for women who can safely use it. If you prefer dietary approaches, trying soy foods (tofu, edamame, soy milk) for 2-3 months is reasonable—about 50% of women in trials get meaningful relief.

For general health during menopause, a Mediterranean-style eating pattern makes sense—not because it’s “anti-inflammatory” but because it’s associated with lower cardiovascular risk, better blood sugar control, and possibly better bone health. These are things menopausal women actually need.

The Bottom Line

When you see “anti-inflammatory diet for menopause,” translate it as: “eat vegetables and fish, which is fine advice dressed up in sciency language.”

The inflammation story isn’t entirely wrong—estrogen loss does increase inflammatory markers. But the leap from “inflammation increases” to “eating turmeric will fix your menopause” is marketing, not medicine.

Your grandmother’s advice to eat your vegetables didn’t need a mechanism. It doesn’t need one now either.

“Women Deserve Data, Not Dogma” This slogan captures everything that evidence-based medicine should stand for - and everything that’s gone wrong in how health information reaches menopausal women today. From wellness influencers hawking unproven supplements to compounding pharmacies marketing “natural” hormones as safer alternatives, midlife women are drowning in advice that prioritizes profit over evidence. The menopause wellness industry has learned that fear of hormones sells, and that “natural solutions” sound safer than FDA-approved medications. Meanwhile, a generation of women has suffered unnecessarily because of misinterpreted data from a single study. But feelings aren’t facts, and “natural” isn’t a safety standard. Here are the facts - not fads - that every menopausal woman deserves to hear.

Subscribe now

Read more

If you open Instagram or walk down the aisle of a pharmacy, you are being sold a lie. It is a very expensive, pastel-colored lie labeled “Hormone Balance,” “Estro-Support,” or “Menopause Relief.”

The supplement industry has realized that menopausal women are a perfect target market: they are suffering, they are often dismissed by the medical establishment, and they have disposable income. The result is what I call the “Menopause Gold Rush”—a multi-billion dollar industry built largely on placebo and pseudoscience.

As a physician, my job is to tell you what works. But sometimes, it is equally important to tell you what does not work, so you can stop burning your money.

The “Natural” Fallacy

The marketing hook is always the same: “Don’t take dangerous pharmaceutical hormones! Take this natural root instead.”

This relies on the “Appeal to Nature” fallacy—the idea that because something is a plant, it is safe and effective. Arsenic is natural. Hemlock is natural. “Natural” does not mean “Safe,” and it certainly does not mean “Effective.”

Let’s look at the data on the “Big Three” supplements you are likely being sold.

1. Black Cohosh: The Queen of the Graveyard

Black Cohosh is the most popular supplement for hot flashes. It has been studied extensively.

A comprehensive Cochrane Review—the gold standard of evidence-based medicine—analyzed 16 randomized controlled trials involving over 2,000 women. Their conclusion? There is insufficient evidence to support the use of black cohosh for menopausal symptoms [1]. The data showed no significant difference between the supplement and a sugar pill.

Furthermore, “natural” does not mean risk-free. There have been multiple case reports linking Black Cohosh to liver toxicity [2]. While rare, it is a real risk for a drug that provides no proven benefit.

2. Evening Primrose Oil

This is often touted for “hormonal balance.” The data is even starker here. Multiple studies have found that Evening Primrose Oil is no more effective than placebo for treating hot flashes [3]. It is essentially expensive salad dressing in a capsule.

3. The “Hormone Balancing” Gummies

These are the worst offenders. They often contain “proprietary blends” of vitamins, soy isoflavones, and herbs. Because supplements are not regulated by the FDA like drugs, you have no guarantee that the pill actually contains what the bottle says. Study after study has shown that many supplements contain practically none of the active ingredient, or worse, are contaminated with unlisted substances.

The 50% Placebo Problem

Why do your friends swear these work? Why do the Amazon reviews look so good?

Welcome to the Placebo Effect.

In clinical trials for hot flashes, the “placebo response” is massive—often between 30% and 50%. That means if I give 100 suffering women a Tic-Tac and tell them it will cure their night sweats, 50 of them will feel significantly better.

The brain is powerful. The relief is “real” to the patient, but it is not caused by the root or the herb. It is caused by the belief in treatment. The supplement companies are selling you a very expensive placebo.

What Actually Works (Non-Hormonal)

If you cannot or do not want to take Hormonal Therapy (MHT), there are non-hormonal options that beat the placebo in clinical trials. These include:

• Veozah (Fezolinetant): A new FDA-approved non-hormonal drug that targets the temperature control center in the brain.

• SSRIs/SNRIs: Certain low-dose antidepressants (like Paroxetine) have proven efficacy for vasomotor symptoms.

• CBT (Cognitive Behavioral Therapy): Specifically designed for menopause, this has robust data supporting its ability to help women manage symptoms.

My Advice

Stop buying the “Menopause Support” gummies. Stop buying the “Hormone Balancing” teas.

If you want to treat your symptoms, we have tools—both hormonal and non-hormonal—that have survived the scrutiny of peer review. You deserve medicine that works, not marketing that exploits your suffering.

References

1. Leach MJ, Moore V. Black cohosh (Cimicifuga racemosa) for menopausal symptoms. Cochrane Database Syst Rev. 2012;(9):CD007244. doi:10.1002/14651858.CD007244.pub2

2. Teschke R. Black cohosh and suspected hepatotoxicity: inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm. A critical review. Menopause. 2010;17(2):426-440. doi:10.1097/gme.0b013e3181c5159c

3. Chenoy R, Hussain S, Tayob Y, O’Brien PM, Moss MY, Morse PF. Effect of oral gamolenic acid from evening primrose oil on menopausal flushing. BMJ. 1994;308(6927):501-503. doi:10.1136/bmj.308.6927.501

If you were alive in July 2002, you remember the news. It didn’t just break; it exploded. The Women’s Health Initiative (WHI) study—the largest randomized controlled trial of its kind—was halted early. The headlines were terrifying: “Hormones Cause Cancer.” “HRT is Deadly.”

Overnight, millions of women flushed their pills down the toilet. Doctors, afraid of being sued or harming patients, stopped prescribing. We witnessed a mass medical exodus from Menopausal Hormone Therapy (MHT).

Two decades later, we can look at the wreckage of that moment with a clear, scientific eye. And the conclusion from the data is tragic: We got it wrong. And by getting it wrong, we harmed a generation of women.

Today, I want to walk you through what the data actually said then, what it says now, and why for most women, the fear of estrogen is unfounded.

The Fatal Flaws of 2002

To understand why the 2002 panic was misguided, you have to look at who was studied.

In scientific research, if you want to know if a drug is safe for a 50-year-old woman entering menopause, you should study 50-year-old women. The WHI didn’t do that. The average age of participants in the study was 63 years old. Many were in their 70s. These were women who had been menopausal for 10, 15, or 20 years before they took their first pill.

Furthermore, the study primarily tested one specific formulation: conjugated equine estrogens (CEE) combined with medroxyprogesterone acetate (MPA), a synthetic progestin.

The study found a small increase in breast cancer and cardiovascular events. But applying those risks to a symptomatic 51-year-old was a statistical error of massive proportions. We now know that starting hormones 15 years after menopause is biologically different from starting them at the onset.

The “Timing Hypothesis”

This brings us to the most critical concept in menopause management: the “Window of Opportunity.”

The data now clearly supports the “Timing Hypothesis.” When estrogen is initiated within 10 years of menopause (usually ages 50-60), it is generally cardioprotective. It keeps blood vessels pliable and reduces the accumulation of coronary artery calcium.

However, if you wait until age 70—when the arteries have already hardened with plaque—and then introduce hormones, you can destabilize that plaque and cause clots.

The WHI gave hormones to women with established vascular aging and saw adverse events. We then told 50-year-old women with healthy arteries that they would suffer the same fate. We were wrong.

The Mortality Toll of Fear

The tragedy is not just that women suffered through hot flashes, insomnia, and brain fog needlessly (though they did). The tragedy is that women died.

In 2013, researchers analyzed the impact of the mass cessation of estrogen therapy following the 2002 scare. The results were sobering. The study, published in the American Journal of Public Health, estimated that between 2002 and 2011, approximately 18,601 to 91,610 excess deaths occurred among women in the United States who had undergone a hysterectomy and were advised to avoid estrogen therapy [2].

Estrogen protects the bones. It protects the heart. By scaring women away from it, we saw a rise in osteoporotic fractures and cardiovascular mortality.

The Current Verdict

So, where do we stand today? We rely on the most recent, comprehensive guidelines, specifically the 2022 Position Statement from The North American Menopause Society (NAMS).

Their conclusion is clear:

“For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and for the prevention of bone loss.” [3]

Furthermore, long-term follow-up of the original WHI participants has shown that for women who started treatment between ages 50 and 59, there was no increased risk of all-cause mortality [4].

My Advice to You

If you are suffering from menopausal symptoms—hot flashes, night sweats, sleep disruption, or brain fog—do not let a headline from 2002 dictate your health in 2026.

1. Context Matters: If you are within 10 years of your final period, the safety profile of MHT is excellent.

2. Formulation Matters: We now often prescribe transdermal estrogen (patches or gels) and micronized progesterone, which have safer profiles than the synthetic pills used in 2002.

3. Individualize: Medicine is not one-size-fits-all. Your history matters.

Do not accept suffering as a “natural” part of aging that you must endure. Science has moved on. It is time you did too.

References

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. doi:10.1001/jama.288.3.321

2. Sarrel PM, Njike VY, Vinante V, Katz DL. The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years. Am J Public Health. 2013;103(9):1583-1588. doi:10.2105/AJPH.2013.301295

3. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028

4. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials. JAMA. 2017;318(10):927-938. doi:10.1001/jama.2017.11217

The Retrospective Mirror and the Clinical Reality

If I had a dollar for every patient who asked to “test their hormones” for menopause, I could fund a new hospital wing. It is a reasonable request, given that we rely on blood work for conditions like diabetes or anemia, but the biology of the ovary resists such simple quantification.

The fundamental misunderstanding lies in the definition itself: menopause is technically a single day in a woman’s life, marked retrospectively exactly 12 months after her last menstrual period.

Before that specific date, a woman is in perimenopause, a turbulent journey that resists a binary diagnosis. Because we often diagnose menopause only by looking backward after bleeding has ceased for a year, patients seeking help during the transition are frequently left confused.

The gold standard for diagnosing this transition is not a laboratory value, but a careful clinical history.

If a woman is over 45 and experiencing the hallmark chaos of irregular cycles—whether they are shortening to 24 days or skipping months entirely—she is diagnostically in the menopausal transition regardless of what a blood test says.

Decoding the Signal Noise: Symptoms Over Lab Values

The body provides a far more accurate diagnostic panel than any phlebotomist can offer. Beyond the menstrual irregularity that signals dwindling ovarian reserve, the presence of vasomotor symptoms serves as a primary confirmation. The classic hot flash, a result of a narrowed thermoneutral zone in the hypothalamus, affects the vast majority of women and often escalates into night sweats that wreck sleep architecture and cognitive function.

Furthermore, the Genitourinary Syndrome of Menopause (GSM) provides a distinct, progressive marker. Unlike hot flashes which may wax and wane, the thinning of estrogen-dependent tissues in the vagina and bladder persists and worsens, manifesting not just as dryness or pain, but often as urinary urgency or recurrent infections. When a patient presents with this constellation of cycle chaos, internal heat, and urogenital changes, the diagnosis is established by the symptoms themselves. Dismissing these signs in favor of a “normal” blood test is a failure of clinical judgment.

The Global Medical Consensus

Major medical societies worldwide have moved in lockstep to discourage the use of hormonal testing for diagnosing menopause in women over 45.

• The National Institute for Health and Care Excellence (NICE) in the United Kingdom explicitly states that otherwise healthy women over 45 should be diagnosed based on clinical history and symptoms alone, without confirmatory laboratory tests.

• Similarly, The Menopause Society (formerly NAMS) and the American College of Obstetricians and Gynecologists (ACOG) emphasize that the diagnosis is clinical, noting that FSH levels are misleadingly variable during the transition.

These guidelines exist to protect patients from unnecessary costs and the diagnostic confusion of receiving “normal” results while experiencing obvious symptoms.

The Fallacy of Follicle Stimulating Hormone

Despite the clarity of clinical symptoms and official guidelines, the market is flooded with “menopause test kits” that prey on the desire for hard data. The reality is that hormonal testing like Follicle Stimulating Hormone (FSH) is scientifically unreliable during perimenopause.

FSH levels are volatile during this window; a woman can register a “menopausal” level on a Monday and a “fertile” level by Thursday as her ovaries sputter and surge. A snapshot of estradiol is similarly useless, as estrogen levels often ride a rollercoaster of super-ovulation spikes and crashes rather than a steady decline.

While Anti-Mullerian Hormone (AMH) can indicate low egg count, it cannot predict the timing of the final period. The only blood test truly necessary in this window is TSH, to rule out thyroid disease which mimics menopausal fatigue and brain fog. We must stop treating menopause as a number to be fixed; we treat the suffering and the symptoms, not the lab results.

The most common patient we see for menopause consultation is 58 years old. She has been suffering from hot flashes and insomnia for seven years. She tells me, “I tried to do it naturally, but I just can’t take it anymore. I’m finally ready for hormones.”

It breaks my heart to tell her that, in some ways, she may be too late for the full benefits.

In medicine, timing is everything. If you treat a stroke in hour one, you save the brain. If you treat it in hour ten, the damage is done. Menopause has a similar, though slower, clock. It is called the “Timing Hypothesis,” and understanding it is critical for your long-term heart and bone health.

The Biology of “Toughing It Out”

Many women view menopause symptoms as a test of character. They believe that enduring the hot flashes makes them “strong” and that taking hormones is “giving in.”

This is a dangerous misconception. The loss of estrogen is not just about feeling hot; it is about the rapid acceleration of aging in your arteries and bones.

Estrogen is a powerful anti-inflammatory for your blood vessels. It keeps the endothelial lining of your arteries flexible and healthy. When estrogen disappears at age 51 (the average age of menopause), that protection vanishes. Plaque begins to build up. Arteries stiffen.

The Data: The ELITE Trial

We don’t just guess about this; we have proof from the ELITE Trial (Early versus Late Intervention Trial with Estradiol), published in the New England Journal of Medicine.

Researchers tested the “Timing Hypothesis” by dividing women into two groups: those early in menopause (<6 years) and those late in menopause (>10 years). They measured the thickness of their carotid arteries (a marker for atherosclerosis).

The results confirmed what we suspected:

• Early Group: Women who started estrogen early saw a significantly slower progression of atherosclerosis. The hormones protected their arteries [1].

• Late Group: Women who started estrogen late (10+ years after menopause) saw no cardiovascular benefit. The window had closed.

Why You Can’t Wait Until 65

This is why the “tough it out” strategy fails. If you wait until age 65—when your arteries have already hardened with plaque—reintroducing estrogen can be risky. It might destabilize that plaque and cause a clot (which is exactly what happened in the older women of the 2002 WHI study).

But if you start at 51, you maintain the health of those arteries. You aren’t just treating hot flashes; you are potentially preventing heart disease, which remains the #1 killer of women.

My Advice

Do not wait until you are “breaking” to fix the problem.

1. The Golden Decade: The safest and most beneficial time to start MHT is within 10 years of your final period (ages 50–60).

2. Bone Health: The most rapid bone loss happens in the first 2-3 years of menopause. Starting therapy early locks in your bone density before it disappears.

3. Don’t be a Martyr: There is no medal for suffering through sleep deprivation and vascular aging. Treating menopause early is proactive preventative medicine.

References

1. Hodis HN, Mack WJ, Henderson VW, et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. N Engl J Med. 2016;374(13):1221-1231. doi:10.1056/NEJMoa1505241

2. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028

3. Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015;(3):CD002229. doi:10.1002/14651858.CD002229.pub4

I see a specific paradox every week. A patient will come in, looking fantastic at 55. She dyes her hair to cover the gray. She uses expensive retinol creams to prevent wrinkles. She may even get Botox injections to freeze the aging process on her forehead.

But when I suggest vaginal estrogen to treat her dryness, pain, and recurring UTIs, she recoils. “Oh no, Dr. Amos, isn’t that dangerous? I don’t want to take hormones.”

This is a failure of medical communication. We have allowed you to believe that vaginal estrogen is a scary systemic drug. It is not. It is essentially “face cream for the vagina.” And avoiding it isn’t just uncomfortable—it is causing you progressive, irreversible harm.

The “Silent” Epidemic: GSM

Unlike hot flashes, which usually stop after a few years, vaginal aging does not get better. It gets worse.

The condition is called Genitourinary Syndrome of Menopause (GSM). Without estrogen, the tissues of the vagina, vulva, and urethra become thin, dry, and fragile. The pH changes, killing off the “good” bacteria (Lactobacilli) and inviting the “bad” bacteria (E. coli).

This leads to painful sex (dyspareunia), tearing, and—most dangerously—recurrent Urinary Tract Infections (UTIs).

The Data: Local vs. Systemic

The fear comes from the 2002 WHI study I discussed in my previous article. But that study looked at systemic hormones (pills you swallow that go into your blood).

Vaginal estrogen is local.

When you apply a low-dose estrogen cream or insert a tablet vaginally, the hormone stays in the tissue where it is needed. It does not circulate through your body in significant amounts.

A pivotal study published in Menopause (the NAMS journal) confirmed that low-dose vaginal estrogen products generally result in serum estradiol levels that remain within the normal postmenopausal range [1]. In plain English: Your blood does not “know” you are taking it. It fixes the tissue locally without affecting your breasts or your heart.

The UTI Connection

This is about more than just painful sex. It is about infection control.

For older women, urosepsis (a UTI that spreads to the blood) is a major cause of hospitalization and even death. Vaginal estrogen is one of our most powerful tools to prevent this.

A Cochrane Review—analyzing data from over 3,000 women—found that vaginal estrogen significantly reduced the recurrence of UTIs in postmenopausal women [2]. It restores the acidic pH and the natural defense barrier.

My Advice

Think of vaginal estrogen like sunscreen or moisturizer. You apply it to your face to keep the skin elastic and healthy. You should apply estrogen to your pelvis for the exact same reason.

1. Start Early: Do not wait until sex is agonizing. Preventing atrophy is easier than reversing it.

2. It is Forever: Unlike hot flash medication, this is a maintenance therapy. If you stop, the atrophy returns.

3. Ignore the Box: The FDA requires a “Black Box Warning” on all estrogen products, even low-dose local ones. The medical community (including NAMS and ACOG) has lobbied to have this removed because it is misleading and not supported by the data for local estrogen [3].

References

1. Santen RJ. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric. 2015;18(2):121-134. doi:10.3109/13697137.2014.947254

2. Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev. 2008;(2):CD005131. doi:10.1002/14651858.CD005131.pub2

3. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-992. doi:10.1097/GME.0000000000001609

It usually happens like this: You walk into the kitchen and stop dead. You have absolutely no idea why you are there. Or you are in a meeting, and a common word—a word you have used a thousand times—vanishes from your brain.

For many of my patients, this isn’t just annoying; it is terrifying. They sit in my office, voice trembling, and whisper the question they are too afraid to ask their partners: “Dr. Amos, is this early Alzheimer’s?”

If this sounds like you, I have good news. You are not going crazy. You are not developing dementia. You are experiencing a very real, measurable, and often temporary neurological event caused by the withdrawal of estrogen.

It Is Not “Just Stress”

For years, women were told their midlife forgetfulness was due to the stress of aging parents, teenage children, or career pressure. While those factors don’t help, we now have imaging proof that something profound is happening inside the skull.

The brain is an energy-hungry organ. It runs on glucose. And for 40 years, estrogen has been a key part of the system that helps your brain cells burn that glucose for energy. Estrogen receptors are densely packed in the hippocampus (memory) and the prefrontal cortex (executive function).

When your estrogen levels crash during perimenopause, your brain essentially faces a “bioenergetic crisis.”

The Data: The “Starving” Brain

We owe a debt of gratitude to neuroscientist Dr. Lisa Mosconi. Her team used PET scans to look at the brains of perimenopausal women. The results were striking.

The scans showed a significant drop in cerebral glucose metabolism—essentially, the brain’s ability to produce energy—during the menopausal transition [1]. In her images, a pre-menopausal brain lights up with activity. A perimenopausal brain looks darker and less active in those key memory centers.

Your brain isn’t broken; it is temporarily starving. It is struggling to function without the fuel additive (estrogen) it has relied on for decades.

The “Dip and Rebound”

Here is the most comforting data I can give you.

The Study of Women’s Health Across the Nation (SWAN) is a massive longitudinal study that followed over 2,000 women as they went through menopause. They tested their cognitive speed and memory repeatedly over years.

The researchers found a distinct pattern: Women experienced a decline in cognitive processing speed and memory during late perimenopause. But here is the key: For many women, this was temporary. Post-menopause, the brain adapted, and cognitive performance often rebounded to pre-menopausal levels [2].

This suggests that “brain fog” is a transition state—a rocky bridge your brain has to cross as it rewires itself to work without high levels of estrogen.

My Advice

1. Stop Panicking: Anxiety eats up bandwidth your brain desperately needs. Know that this is a physiological phase, not a permanent decline.

2. Consider MHT: If your brain fog is severe, Menopausal Hormone Therapy (MHT) can help. By restoring estrogen, we can often “turn the lights back on” in those glucose-starved neurons.

3. The “Mediterranean” Lifestyle: Dr. Mosconi’s data suggests that antioxidants and a diet rich in omega-3s can help buffer this metabolic drop.

You aren’t losing your mind. You are just upgrading your operating system.

References

1. Mosconi L, Berti V, Quinn C, et al. Perimenopause and emergence of an Alzheimer’s bioenergetic phenotype in brain and periphery. PLoS One. 2017;12(10):e0185926. doi:10.1371/journal.pone.0185926

2. Greendale GA, Huang MH, Wight RG, et al. Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology. 2009;72(21):1850-1857. doi:10.1212/WNL.0b013e3181a71193

3. Maki PM, Jaff NG. Brain fog in menopause: a health-care professional’s guide for decision-making and counseling on cognition. Climacteric. 2022;25(6):570-578. doi:10.1080/13697137.2022.2122792

When American OB-GYNs are too busy “doing” to listen, women turn to WhatsApp for care. Perimenopause is exposing the moral cost of a healthcare system that doesn’t pay for time. It pays for procedures.

Subscribe now

Perimenopause marks the hormonal transition between the reproductive years and menopause, often beginning in a woman’s 40s but sometimes earlier. It can last many years, even decades. Estrogen and progesterone levels fluctuate unpredictably, causing symptoms like insomnia, hot flashes, mood changes, and irregular bleeding. Though universal and entirely normal, this phase has been poorly understood and rarely prioritized in medical training, leaving many women to navigate it alone or seek answers outside traditional medical care.

Perimenopause is not a mystery of nature. It’s a predictable, physiologic transition that happens to half the human race. Yet in the United States, finding a doctor who will talk about it can feel like trying to get into a secret club - one that only accepts patients who “know someone.”

Let’s start with what perimenopause actually is. It’s the years leading up to menopause, when estrogen and progesterone begin to fluctuate and the menstrual cycle becomes irregular. It can bring hot flashes, brain fog, hair loss, night sweats, insomnia, weight changes, mood shifts, and vaginal dryness. Most women will experience some of these. None of it should be mysterious. Yet across the country, it’s becoming a scavenger hunt for care.

Many American women discover that their OB-GYNs - the very specialists expected to guide them through the reproductive lifespan - are largely unprepared to address perimenopause. Annual visits are often reduced to five-minute checkups focused on Pap smears and contraception. Patients report being dismissed with phrases like “you’re too young” or “it’s just stress.” The result: millions of women turn to book clubs, WhatsApp groups, or Instagram threads for medical advice their doctors never offered.

This silence isn’t accidental. It’s structural.

The Economics of Listening

In modern American Ob/Gyn, time doesn’t pay. Procedures do. Deliveries, surgeries, and IVF cycles generate income; counseling does not.

It’s no wonder that reproductive endocrinologists, the IVF doctors, often pivot to selling “hormone optimization” or “menopause management” packages that promise vitality, youth, and balance.

A single IVF cycle can cost $20,000 to $40,000, most of it cash, and many clinics have learned that the same women seeking fertility treatments may later be drawn to other profitable “wellness” procedures.

The business model naturally expands: hormone pellets, compounded estrogen creams, thyroid “tuning,” Botox, fillers, cosmetic labiaplasties, and “vaginal rejuvenation” surgeries—all cash-based services that can cost thousands of dollars each and require no insurance oversight. In this hybrid space between reproductive medicine and beauty marketing, the financial incentives are clear. Time spent counseling earns nothing, while every injection, cycle, or incision pays.

Meanwhile, the average Ob/Gyn visit lasts seven minutes face-to-face. That’s barely enough to address one problem, much less unravel the complex hormonal, emotional, and relational changes of perimenopause. Clinicians aren’t heartless; they’re trapped in a system that punishes time and rewards volume.

The Whisper Network

Out of that void, a “whisper” network has emerged. Women text one another the names of “good” doctors, ones who listen, who take insurance, who actually discuss hormone replacement therapy (HRT). This underground exchange of medical leads has become as essential as a prescription.

Telehealth startups have jumped in to fill the gap. Platforms like Midi and Alloy Health now market themselves as the empathetic alternative to rushed OB-GYN practices. They offer virtual hormone consultations and overnight prescriptions. All fdor good $$. For some, this is a lifeline. For others, it’s just another paywall.

$Billions are invested in these companies, and most of these companies rely on direct-to-consumer advertising and out-of-pocket fees. Once again, access depends on income.

A Professional Failure

The failure here isn’t technological—it’s professional.
When women report fatigue, brain fog, or sexual pain, they are describing real physiologic shifts. Dismissing them as “stress” or “aging” is not evidence-based medicine. It’s neglect.

Part of the blame lies in how obstetrics has defined its boundaries. For decades, OB-GYN training emphasized what one doctor called “bikini medicine”: breasts, uterus, ovaries. Everything between puberty and pregnancy was fair game; everything after was an afterthought. That mindset persisted even as life expectancy increased and menopause became one-third of a woman’s life.

The 2002 Women’s Health Initiative study—widely misreported—only deepened the retreat. When early headlines suggested that hormone therapy caused heart attacks and cancer, doctors stopped prescribing it. What many missed was that the study’s risks applied mainly to women over 60 starting therapy late. For women in their 40s and 50s, evidence now shows that HRT is both safe and beneficial for most. But the damage to public and professional confidence remains.

The Bigger Picture

This isn’t just about menopause. It’s about a profession that has allowed financial incentives and bureaucratic constraints to silence its own human core. American obstetrics has become a field of “doers,” not “discussers.” The averag ObGyn makes over 3-4 times their European counterparts, and much more for procedures. The same problem shows up elsewhere: contraception counseling rushed into two minutes, miscarriage care outsourced to urgent care, postpartum depression treated as an afterthought.

We’ve built a healthcare economy that reimburses doing, cutting, scanning, and injecting—but not explaining. When a woman wants to talk about why her periods are erratic or why sex has become painful, she’s not asking for a luxury service. She’s asking for medicine.

What Needs to Change

Reform must start in residency. Future OB-GYNs need structured, evidence-based education on perimenopause, menopause, and sexual function—not as electives, but as core clinical competencies.

Health systems must change reimbursement models to pay for time and communication. A 30-minute visit discussing hormonal therapy, sexual health, or lifestyle medicine is worth as much as any ultrasound or biopsy. But gets reimbursed at 1/10th that.

Finally, professional societies like ACOG must reclaim the narrative. It should not take celebrity podcasts or influencer clinics to tell women that perimenopause is real and treatable.

The ethical principle of beneficence demands more than doing procedures—it requires doing good. That means listening.

Reflection / Closing:
Medicine shouldn’t depend on a whisper network. When the only way to find care is through a friend’s text thread, the system has already failed. The next revolution in women’s health will not come from a new hormone patch or an app; it will come when doctors are paid, trained, and expected to listen.

Will we keep building clinics that “do more,” or finally rebuild one that hears better?

Here are seven trustworthy, non-commercial resources that genuinely support women through perimenopause and menopause:

1. Let’s Talk Menopause – A U.S. nonprofit dedicated to education and awareness. It offers free webinars, podcasts, and resources to help women understand perimenopause without pushing products.

https://www.letstalkmenopause.org

2. National Menopause Foundation – Focused on building community and advocacy around midlife health, this foundation provides fact-based education and public health resources.

https://nationalmenopausefoundation.org

3. The Menopause Society (formerly NAMS) – A respected nonprofit professional society that also runs public education campaigns and a free directory of certified menopause practitioners. https://menopause.org

4. The Menopause Foundation of Canada – A national charity working to improve awareness, research, and workplace support for women in perimenopause and menopause.

https://menopausefoundationcanada.ca

5. Society for Women’s Health Research (SWHR) – A Washington-based nonprofit advocating for research and policy that address women’s unique health needs, including hormonal transitions.

https://swhr.org

6. The Menopause Charity (UK) – Founded by medical professionals and patient advocates, this UK charity offers clear, evidence-based information and free support for women experiencing menopause.

https://themenopausecharity.org

7. Daisy Network – A UK-based charity providing education, emotional support, and peer connections for women with primary ovarian insufficiency and early menopause.

https://www.daisynetwork.org

Menstruation follows ovulation, not the other way around. Every menstrual cycle begins not in the uterus but first in the brain, then the ovary and finally the uterus. When the brain tells the ovary not to ovulate, not to release the egg, when ovulation stops or occurs less often, menstruation stops too. The regular monthly bleeding that most women call a “period” or “menstruation” is the body’s signal that ovulation has occurred, fertilization did not, and the uterine lining is being shed. Women can bleed and spot without ovulation, but when it’s not regular, it’s not regular menstruation, it’s not a “period”.

Subscribe now

• Period (Menstrual Period): A period is the monthly bleeding that follows ovulation when pregnancy has not occurred. It results from the shedding of the uterine lining as hormone levels fall. True menstruation requires prior ovulation; bleeding without ovulation is not a true period but anovulatory bleeding.

• Ovulation is the release of an egg from the ovary, triggered by a mid-cycle surge in luteinizing hormone (LH). It marks the moment when reproduction is possible.

• Menorrhea or Menstruation, by contrast, is the shedding of the endometrial lining approximately two weeks later if pregnancy has not occurred. Without ovulation, there is no luteal phase, no progesterone withdrawal, and therefore no true menstrual bleeding.

This sequence explains why pregnancy and menopause themselves are a physiologic (“normal”) form of amenorrhea, of missing a regular period. Once conception occurs, ovulation halts—human chorionic gonadotropin (hCG) and high progesterone levels suppress the hypothalamic-pituitary-ovarian axis to maintain the uterine lining and prevent further ovulation. In a normal pregnancy, menstruation ceases because the hormonal cycle that drives it is intentionally interrupted. Any bleeding that occurs during pregnancy is not menstruation but abnormal uterine bleeding from implantation, placenta, or cervical changes.

Here are medical terms for abnormal menses/periods

• Amenorrhea: Absence of menstrual periods—can be primary (never started) or secondary (stopped after previously normal cycles).

• Hypomenorrhea: Unusually light or scant menstrual bleeding.

• Oligomenorrhea: Infrequent menstrual periods, typically occurring more than 35 days apart.

• Polymenorrhea: Abnormally frequent menstrual cycles, usually less than 21 days apart.

• Menorrhagia: Excessive or prolonged menstrual bleeding at regular intervals.

• Metrorrhagia: Bleeding between periods or at irregular intervals.

• Menometrorrhagia: Heavy and irregular bleeding, combining features of menorrhagia and metrorrhagia.

• Dysmenorrhea: Painful menstruation, often associated with cramping or pelvic discomfort.

The Physiologic Sequence: From Brain to Bleeding

In a healthy, ovulatory cycling woman, the hypothalamus releases GnRH in rhythmic pulses. The pituitary responds by secreting FSH and LH, which stimulate the ovaries to mature follicles and produce estrogen. Around mid-cycle, the LH surge triggers ovulation—the release of an egg. Afterward, the follicle becomes the corpus luteum, secreting progesterone that stabilizes the uterine lining in anticipation of pregnancy.

If fertilization does not occur, progesterone levels fall. The endometrium loses its hormonal support and breaks down, resulting in menstrual bleeding—the visible endpoint of a cycle that began weeks earlier in the brain.

Share

When energy deficiency, psychological stress, or disease disrupts this sequence, the hypothalamus stops releasing GnRH. Without that pulse, the pituitary does not release LH or FSH, and the ovary does not ovulate. Without ovulation, the uterine lining remains thin, and menstruation ceases. The result is amenorrhea, a visible sign of invisible anovulation.

The Body’s Emergency Mode

My mother, imprisoned by the Nazis during World War II, stopped menstruating within months of arrival in the camps. She believed, as many did, that the Nazis had injected women with hormones to prevent fertility. In truth, no injection was necessary. Her ovulation had stopped because her body, starved and terrified, had no resources to sustain reproduction. Also, when she lost weight, ovulation stopped. What she experienced was functional hypothalamic amenorrhea—the brain’s emergency command to halt ovulation and conserve energy.

Studies of Holocaust survivors later confirmed this pattern. Nearly all menstruating women stopped ovulating and bleeding shortly after internment, a direct consequence of starvation and extreme stress. Menstrual cycles typically resumed months after liberation when nutrition and safety and normal weights returned. For many, the first period after the war was a deeply emotional event—a physiological declaration that life had resumed. And consequently there was an increase in fertility.

Primary ovarian insufficiency (POI), Perimenopause, and Menopause

• Primary ovarian insufficiency (POI) previously known as Premature ovarian failure—occurs when the ovaries stop functioning before age 40, leading to irregular or absent ovulation and amenorrhea due to depleted or unresponsive follicles.

• In contrast, perimenopause is the natural transitional phase leading up to menopause, characterized by fluctuating hormone levels, irregular ovulation, and variable bleeding patterns such as oligomenorrhea or menometrorrhagia.

• Menopause is defined retrospectively after 12 consecutive months without menstruation, reflecting the permanent cessation of ovulation and estrogen production. These stages represent a continuum of declining ovarian activity and mark the gradual end of reproductive capacity.

The Modern Mirror: Athletes and Amenorrhea

The same biology operates today under different names. In athletes, dancers, and women with eating disorders, ovulation often stops when energy intake cannot meet physical demands. This athletic amenorrhea arises from the same hypothalamic suppression seen in famine. Low energy availability signals the brain that it cannot afford reproduction. Ovulation ceases, estrogen falls, and menstruation disappears.

This is not a benign adaptation. Estrogen deficiency leads to loss of bone mineral density, stress fractures, and premature osteoporosis. The so-called female athlete triad—low energy availability, amenorrhea, and low bone mass—remains a major health risk. In adolescents, it can permanently impair peak bone formation. Fertility usually returns when ovulation resumes, but chronic suppression may leave lasting skeletal and endocrine effects.

Over time, prolonged hypothalamic suppression can mimic or mask premature ovarian insufficiency (POI), a condition in which the ovaries themselves fail to produce normal levels of estrogen and viable follicles before age 40. In true POI, ovarian reserve is depleted or the follicles no longer respond to gonadotropins, leading to persistently elevated FSH and irreversible amenorrhea. In contrast, athletic or stress-related amenorrhea reflects a reversible central (hypothalamic) suppression of otherwise normal ovaries.

While most athletes with functional hypothalamic amenorrhea do not have true POI, years of undernutrition and hormonal suppression may accelerate follicular loss or unmask underlying ovarian vulnerability. If menses and ovulation do not resume after nutritional rehabilitation and normalization of weight, evaluation for POI becomes essential. In these cases, the distinction is both diagnostic and prognostic: hypothalamic amenorrhea can recover, but POI signifies permanent loss of ovarian function and early estrogen deficiency with implications for bone, cardiovascular, and cognitive health.

Thus, the absence of menstruation in athletes should never be dismissed as a normal effect of training. Whether temporary or permanent, it signals a disturbance in the reproductive axis that demands investigation and, when possible, restoration of ovulatory function.

Pregnancy, Ovulation, and the Meaning of Normal

Pregnancy itself is the best illustration of the link between ovulation and menstruation. During pregnancy, the ovary’s corpus luteum and then the placenta produce high levels of estrogen and progesterone, maintaining the uterine lining and suppressing new ovulation. The absence of menses in pregnancy is entirely normal because the reproductive system has already succeeded in its goal—life is growing, and another ovulation is unnecessary.

Outside pregnancy, however, the absence of menstruation almost always means one thing: no ovulation. The causes may vary—starvation, stress, endocrine disease, or athletic overexertion—but the physiology is identical.

In each case, the absence of bleeding is not just a gynecologic event but a systemic one. The body is making a trade-off: conserving calories, diverting energy to vital organs, and deferring reproduction until conditions improve.

Amenorrhea Is a Message

Amenorrhea, whether from pregnancy, trauma, or overtraining, is the body’s way of communicating priorities. It says: Not now. Not until it’s safe. The mechanism is ancient and protective, but modern culture often misreads it. When a woman misses her period and is not pregnant, the absence is not “normal.” It is a sign that the body’s hormonal axis has withdrawn reproductive permission.

In clinical practice, distinguishing true menstruation from other bleeding is crucial. Menstrual bleeding follows ovulation and hormonal withdrawal; anovulatory bleeding may occur unpredictably from endometrial instability without prior ovulation. This distinction is central to diagnosis and management. A woman can bleed without ovulating, but she cannot menstruate without ovulating first.

Ethics and the Language of Health

For my mother, amenorrhea in Auschwitz symbolized deprivation and survival. For athletes and patients today, it often reflects social and cultural pressures to overperform and undernourish. In both settings, the physiology is the same—only the context differs.

Physicians must teach this clearly: menstruation is not a nuisance, and its absence is never trivial. Whether due to pregnancy, stress, or starvation, amenorrhea reveals the body’s priorities. Our role is to interpret that signal, not ignore it.

Reflection

When ovulation stops, the body is protecting itself. Menstruation disappears not because something “went wrong,” but because the reproductive system is wise enough to wait. Pregnancy proves this principle beautifully—when life is already being created, ovulation stops naturally. But when life feels threatened, ovulation stops for the same reason: to safeguard what remains.

In both cases, the absence of bleeding is an act of preservation. The return of ovulation, whether after pregnancy, famine, or recovery, marks the body’s declaration that safety has been restored.

Menstruation follows ovulation. Understanding that sequence transforms how we view both fertility and health. The uterus does not decide when to bleed; the brain decides when it is safe to create life.